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viruses are highly dependent on numerous cellular proteins and processes, and also must evade multiple
antiviral defense mechanisms. Since viral pathogens represent a significant threat both to human health and
agriculture, a better understanding of these interactions could facilitate the treatment of viral infections and
provide novel targets for therapeutics. In particular, Poxviruses include medically important human pathogens
yet little is known about the specific cellular factors essential for their replication. To identify genes essential
for vaccinia infection, I used high-throughput RNA interference to screen Drosophila kinases and
phosphatases. I identified seven genes including the three subunits of AMPK as promoting vaccinia infection.
AMPK facilitated infection both in insect and mammalian cells. I found that AMPK is required for
macropinocytosis, a major endocytic entry pathway for vaccinia. Furthermore, AMPK contributes to other
actin-dependent cellular processes including lamellipodia formation and wound healing, independent of the
known AMPK activators LKB1 and CaMKK. Therefore, AMPK plays a highly conserved role in poxvirus
infection and actin dynamics independent of its role as an energy regulator.
This led me to investigate the role of AMPK in other viral infections, including human arthropod-borne viral
pathogens. Surprisingly I found that AMPK expression and activation restricts infection of the Bunyavirus Rift
Valley Fever Virus (RVFV) in an LKB1-dependent manner. RVFV like other RNA viruses manipulates
cellular membranes to form vesicle-like structures that support the viral replication complex in a process
dependent on de novo fatty acid synthesis. I found that AMPK activation potently inhibits acetyl Co A
carboxylase, crucial in fatty acid synthesis, leading to decreased levels of cellular lipids. Bypassing fatty acid
synthesis by treating cells with palmitate, the first product of fatty acid synthesis rescued infection,
demonstrating that AMPK restricts RVFV by inhibiting fatty acid synthesis. Additional RNA viruses that
require membrane proliferations including the Togavirus Sindbis and the Alphavirus Vesicular Stomatitis
Virus were also restricted by AMPK. AMPK is likely a component of the intrinsic innate immune response
against RNA viruses, and may provide a target for broadly anti-viral therapeutics.
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ABSTRACT 
THE ROLE OF AMPK IN VIRAL INFECTION 
 
Theresa S. Moser 
Thesis Advisor: Sara Cherry 
 
Host factors are crucial in determining the outcome of viral infection. As obligate 
intracellular pathogens, viruses are highly dependent on numerous cellular proteins and 
processes, and also must evade multiple antiviral defense mechanisms. Since viral 
pathogens represent a significant threat both to human health and agriculture, a better 
understanding of these interactions could facilitate the treatment of viral infections and 
provide novel targets for therapeutics. In particular, Poxviruses include medically 
important human pathogens yet little is known about the specific cellular factors 
essential for their replication. To identify genes essential for vaccinia infection, I used 
high-throughput RNA interference to screen Drosophila kinases and phosphatases. I 
identified seven genes including the three subunits of AMPK as promoting vaccinia 
infection. AMPK facilitated infection both in insect and mammalian cells. I found that 
AMPK is required for macropinocytosis, a major endocytic entry pathway for vaccinia. 
Furthermore, AMPK contributes to other actin-dependent cellular processes including 
lamellipodia formation and wound healing, independent of the known AMPK activators 
LKB1 and CaMKK. Therefore, AMPK plays a highly conserved role in poxvirus infection 
and actin dynamics independent of its role as an energy regulator. 
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This led me to investigate the role of AMPK in other viral infections, including 
human arthropod-borne viral pathogens. Surprisingly I found that AMPK expression and 
activation restricts infection of the Bunyavirus Rift Valley Fever Virus (RVFV) in an 
LKB1-dependent manner. RVFV like other RNA viruses manipulates cellular membranes 
to form vesicle-like structures that support the viral replication complex in a process 
dependent on de novo fatty acid synthesis. I found that AMPK activation potently inhibits 
acetyl Co A carboxylase, crucial in fatty acid synthesis, leading to decreased levels of 
cellular lipids. Bypassing fatty acid synthesis by treating cells with palmitate, the first 
product of fatty acid synthesis rescued infection, demonstrating that AMPK restricts 
RVFV by inhibiting fatty acid synthesis. Additional RNA viruses that require membrane 
proliferations including the Togavirus Sindbis and the Alphavirus Vesicular Stomatitis 
Virus were also restricted by AMPK. AMPK is likely a component of the intrinsic innate 
immune response against RNA viruses, and may provide a target for broadly anti-viral 
therapeutics.   
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I. INTRODUCTION 
1. The Study of Virus-Host Interactions Using RNAi Technology 
Since viruses are obligate intracellular pathogens with limited coding capacity, 
they must take advantage of numerous cellular processes and pathways in order to 
complete their lifecycle. At the same time the host has many strategies of anti-viral 
defense that viruses must evade in order to be successful. Since viral pathogens 
represent a significant threat both to human health and agriculture, a better 
understanding of these interactions could facilitate the treatment of viral infections and 
provide novel targets for therapeutics. There are several approaches that can be used to 
identify these host factors. One approach is to use small molecule inhibitors to identify 
cellular mechanisms involved in viral infection.  A drawback to this approach is that 
many small molecules have multiple cellular targets, and often the specific genes 
involved remain unknown. A second approach is to use robust hypomorphic loss of 
function RNA interference (RNAi) methodology. RNAi allows for systematic gene 
silencing of targeted mRNAs, creating a platform for unbiased loss-of-function screening 
in cultured cells. Because whole genomes can be screened without requiring time 
consuming genetic manipulation, RNAi has become a valuable methodology for reverse 
genetic screening [1].  
Cell-based screening in a Drosophila model system is particularly amenable to 
this approach, as it provides an excellent model system to probe the host contribution to 
viral infection through RNAi screening. RNAi silencing is extremely potent in Drosophila 
allowing robust knockdown of the targeted gene, and the reduced redundancy displayed 
in the Drosophila genome increases the likelihood of identifying candidates with single 
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gene RNAi [2,3].   Moreover, many developmental and cell biological processes are 
conserved from Drosophila to mammals, making the fruitfly a good model for studying 
mammalian systems [4]. Cell-based loss of function RNAi screens have been developed 
in Drosophila targeting either the entire genome or a subset of the genome, such as the 
kinase-phosphatase screen I employed in Chapter III [2,5].  
These high-throughput screens that have been generated can be used for many 
different cell biological applications including the study of viral infection [6]. In particular, 
previous studies using these approaches have dissected the host factor requirements of 
Drosophila C Virus (DCV). Using both cell-based screens and fly mutations, clathrin-
mediated endocytosis was identified as an important component of DCV infection and 
pathogenesis [7]. Additional host components were identified through RNAi screens, 
revealing that DCV is also exquisitely sensitive to cellular translation machinery [8]. 
Notably, many of the components identified through these approaches were also 
important for the infection of adult flies with DCV, and for the infection of human cells 
with the related human pathogen, poliovirus [8]. This overlap demonstrates that host 
factors identified in Drosophila can play conserved roles in mammalian systems. 
Moreover host factors were identified that control various steps in the virus life cycle 
including entry, translation, and RNA replication. This approach has also successfully 
been used to identify factors that contribute to the host innate immune response [9].  A 
wide variety of viruses can infect Drosophila cells, and since many medically and 
agriculturally important viruses are carried or transmitted by insects, a greater 
understanding of infection in insects is also beneficial [10]. Thus, studies in Drosophila 
can increase our understanding of the host factors that contribute to viral pathogenesis 
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as well as the host response, and allow the unbiased discovery and dissection of the 
host contribution to viral infection.  
2. Poxvirus Infection and Tropism 
Poxviruses are large double stranded DNA viruses that replicate entirely in the 
cytoplasm of infected cells [11]. This group includes members that infect a diverse group 
of animals, ranging from invertebrate insects (Entomopoxviruses), to vertebrate reptiles, 
birds, and mammals (Chordopoxviruses), giving this group both medical and ecological 
importance. Chordopoxviruses have been divided into eight genera, of which the 
Orthopoxviruses are the best studied. This group includes variola virus, the causative 
agent of smallpox, as well as other similar viruses that contribute to human disease, 
such as cowpox, monkeypox, and vaccinia [12]. Variola virus was declared eradicated 
from nature in 1980 through very successful vaccination campaigns, but frozen stocks 
still exist, and this virus continues to be considered a bioterrorist threat [13].  
Additionally, the closely related cowpox and monkeypox viruses can be transmitted to 
humans zoonotically from their natural rodent hosts and remain a public health concern 
[14].  
The Poxvirus genome consists of a single segment of double stranded DNA 
~200kb long with hairpin loops at the termini. The genome encodes approximately 200 
open frames with nearly a quarter of these genes conserved across all sequenced 
poxviruses [15]. Nearly half of the genes are conserved across Chordopoxviruses 
[15,16]. The majority of these well conserved genes have housekeeping functions 
required in the process of making new progeny virus. Many of the other genes have 
immunomodulatory roles, and are believed to be responsible for the specific species 
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tropism of each virus, which varies greatly [17].  Viruses such as vaccinia, cowpox, and 
monkeypox are able to cause disease in a wide range of animals, while others in this 
group such as Variola, and Ectromelia viruses are restricted to a single species: 
humans, and mice, respectively [12]. Studies with the Leporipoxvirus Myxoma have 
demonstrated that altering the host response to infection can alter viral tropism.  
Myxoma virus is highly specific to infection of rabbits and has an abortive phenotype in 
other species and cell types; however, knocking out the interferon receptor can allow the 
virus to productively infect normally abortive cell types [18,19]. This finding demonstrates 
the importance of the host contribution in determining the outcome of infection.      
3. Vaccinia Virus  
Vaccinia virus is the best studied member of the poxvirus family, and was 
created and used successfully as the vaccine for smallpox, leading to the eradication of 
this disease. Sequence analysis indicates that vaccinia is equally similar to variola and 
cowpox viruses, making it impossible to determine the exact origin of this virus 
[15,20,21]. While the virus is not natural, infection is still a concern in some 
circumstances. Vaccinia is an infectious virus, and there are reports of recently 
vaccininated individuals, particularly soldiers, transmitting the infection to close personal 
contacts [22,23,24,25,26,27,28].  This is a concern since vaccinia infection can cause 
severe illness in some instances [22,24].  
 a. Vaccinia Lifecycle 
 Vaccinia has a complex lifecycle that requires interactions with numerous host 
components. The virus must first attach, enter cells, and uncoat through complex 
mechanisms that will be further discussed below. Once the virus has gained entry into 
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the cytoplasm of the host cell, the virus undergoes several rounds of temporally 
regulated nucleic acid synthesis. The first replication step is the ATP-dependent 
transcription of early genes, which is mediated entirely by viral proteins [29]. The genes 
expressed early in infection include those involved in immune evasion, and also those 
required for DNA replication and intermediate protein synthesis [11]. DNA replication 
along with later stages in the life cycle takes place in virus factories, which are discrete 
partially membrane-bound cytoplasmic foci of replication in the perinuclear region of 
infected cells [30]. Establishment of these factories involves many changes to the 
cellular structure. ER-derived membrane is incorporated into the factories, and virus 
particles traffic along microtubules to reach the perinuclear location of the factories 
[30,31,32,33]. This process may be assisted by induction of cellular motility and 
contractility to collect microtubules and endosomes near the factories, and thus involves 
both the actin and microtubule cytoskeletal networks [31,32,34].  DNA replication begins 
1-2 hours after infection and produces about 10,000 genome copies per cell connected 
in a head-to-head, and tail-to-tail arrangement of concatamers that must be cleaved by 
the viral resolvase in the late stages of infection to produce single genome units for 
packaging [11,35]. A number of virally-encoded factors have important roles in DNA 
replication including the DNA polymerase, nucleoside triphosphatase, DNA glycosylase, 
and processivity factors [11,36]. The viral B1 kinase is also required for DNA replication, 
at least partially through inhibiting a cellular protein BAF that normally binds cytoplasmic 
DNA and blocks replication [37].  Unknown cellular factors also play important roles in 
successful DNA replication, since this step in the lifecycle is frequently blocked in 
abortive cell lines [38,39].  
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Following DNA replication viral gene expression shifts from early to intermediate, 
and then late gene products. Several intermediate genes are required for late gene 
expression, maintaining the lifecycle’s temporal progression. Proteins expressed late 
consist of virion structural components and proteins required for early transcription [29]. 
In addition to virally encoded factors, host factors are required for intermediate and late 
synthesis [40,41,42]. The putative RNA binding protein G3BP and/or p137 are host 
proteins required for intermediate expression [43]. A nuclear transcription factor, 
YinYang (YY1) was shown to be recruited out of the nucleus and bind to an intermediate 
promoter and may have a repressive role [44]. Several nuclear riboproteins A2/B1 and 
RBM3 play redundant roles in late transcription, and may play an important role in 
targeting the replication machinery to the late promoters [45]. Finally, the TATA binding 
protein (TBP) has also been shown to bind intermediate and late promoters and has an 
essential role in transcription at these stages [46].   
 Once these stages of viral replication are completed, assembly of new virions 
begins.  This process includes several stages of morphogenesis within the viral 
replication factories before mature virions are produced, a process that involves the 
trans-Golgi membrane protein golgin-97 [47,48,49]. The maturation process involves 
cresent formation, genome encapsidation, and membrane acquisition. Mature virus 
(MV), the first infectious form of the virus, consists of the virus core, with the DNA 
genome and early replication machinery, surrounded by a single lipid bilayer envelope 
and associated proteins. These virions then have several fates.  MV can remain in the 
cytoplasm of the infected cell until it is released by cell lysis [47]. Alternatively, MV 
particles can use microtubules for transport to the golgi, where they undergo wrapping 
and obtain additional sets of Golgi-derived lipid bilayer envelopes [50]. These 
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membranes are studded with a different set of vaccinia proteins that are trafficked to the 
Golgi during replication. Once wrapping is complete, these virions are transported on 
microtubules to the cell surface, where they fuse with the cell membrane in an actin-
dependent manner, leaving behind the outer-most Golgi-derived envelope [51,52,53]. 
This Extracellular Virus (EV) is a second mature and infectious form of the virus, which 
can dissociate from the cell to facilitate virus spread. Alternatively, EV can remain 
associated with the cell (CEV) and induce Abl family kinase dependent signaling events 
that induce actin tail formation to propel the virion away from the infected cell, and aid in 
its spread to adjoining cells [51,54,55,56]. In addition to facilitating spread of newly made 
EV particles, generation of actin tails can accelerate infection by directing other incoming 
EV particles to surrounding uninfected cells [57]. The different forms of virus are 
believed to have different roles during infection, with the more stable MV particles 
responsible for spread of the virus from host to host, while the EV and CEV forms are 
important in dissemination within a host [51].  
   b. Vaccinia Entry and Macropinocytosis 
 Entry of enveloped viruses such as vaccinia typically occurs in four steps: virus 
attachment, trafficking to an appropriate compartment, activation of fusion proteins, and 
membrane fusion releasing the virus core into the cytoplasm [58]. Attachment may occur 
by several binding events. Evidence suggests that virion binding to cell surface 
glycosaminoglycans can facilitate attachment [59]. Certain vaccinia proteins can also 
bind to cellular chondroitin sulfate and heparin sulfate, which may actually inhibit 
infection, but it is unclear what role if any these binding events have on vaccinia entry 
[59,60,61,62].   
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Many of the viral proteins involved in vaccinia entry have been recently 
characterized. The vaccinia entry fusion complex is made up of at least 8 proteins, but a 
number of others also play a role in entry [63,64,65,66,67,68,69,70,71,72,73,74,75,76]. 
These proteins are expressed late in infection, and are present on the MV membrane. 
Notably, both MV and EV forms of the virus use the same entry fusion complex for virus 
entry, but may have different entry kinetics [77,78]. Since all forms of the virus use the 
same entry-fusion complex, located on the inner MV membrane, this poses an 
interesting problem for EV and CEV virions and necessitates the removal of the outer 
membrane before fusion can occur. The EV membrane is fragile and actively broken 
upon cellular contact. EM images suggest that the EV membrane breaks, but remains 
associated with the virion on the cell surface, providing a sheath that may hide and 
protect the virus particle during entry [79]. Studies have also suggested that EV entry 
requires low pH, presumably because acidic conditions are needed to disrupt the outer 
membrane, but studies have also indicated that MV entry requires low pH, so it is 
unclear if acidity plays a specific role in disruption of the EV membrane [59,80,81].    
The location and cellular requirements of membrane fusion and entry are 
controversial. Electron microscopy studies have shown virus particles fusing at the 
plasma membrane, but it was unclear if this was a productive form of entry [59]. Early 
drug inhibitor studies indicated that actin inhibitors as well as drugs that blocked 
acidification of endosomes were able to block the majority of infection, which led to the 
belief that at least two entry mechanisms existed: fusion at the plasma membrane, or 
pH-dependent endosomal entry [77,78,82]. Since the virus is excluded from many routes 
of endosomal entry by its large size, and it is an actin dependent process, 
macropinocytosis was believed to be the mechanism of endosomal entry [77,83,84]. It 
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has become clear that there are multiple routes for vaccinia entry that are both virus 
strain and cell type specific. Vaccinia strains WR and Wyeth seem to enter 
predominantely using a low pH endosomal mechanism in BSC-1 cells, likely 
macropinocytosis, while IHDJ, Copenhagen, and Elstree are less sensitive to pH, 
indicating that the predominant mechanism of entry is likely fusion at the plasma 
membrane, or a pH-independent endosomal fusion mechanism [85]. Furthermore, 
macropinocytosis seems not to be the the entry mechanism in all cell types.  Both WR 
and IHDJ entry into Chinese Hamster Ovary (CHO) cells is resistant to inhibitors of Na/H 
exchangers, Pak1, and PI3 kinases that are indicative of macropinocytosis [84]. Even 
entry of the same vaccinia strain into different cell types is variable with respect to low 
pH dependence, entry kinetics, and inhibition by heparin [86]. Therefore, additional 
mechanisms of entry exist, and there are many additional cellular factors remaining to be 
identified for this complicated uptake mechanism and thus, for vaccinia entry. 
Recent studies in HeLa cells have demonstrated that macropinocytosis is an 
important endocytic route of vaccinia entry [83]. Generally, macropinocytosis is a 
nonselective route for bulk fluid-phase uptake and is not constitutively active, but is 
induced by growth factors, and also by some pathogens including vaccinia [87,88]. This 
active endocytic process induces extensive actin cytoskeletal rearrangement, leading to 
membrane ruffling, lamellipodia formation, and the internalization of extracellular fluid 
and membrane. Consistent with this, vaccinia entry is dependent upon modulation of the 
actin cytoskeleton, and initiates macropinocytosis by inducing dramatic actin-rich 
microvilli protrusions followed by global myosin II-dependent blebbing, thereby 
promoting virus uptake [78,83]. Induction triggers the activation of receptor tyrosine 
kinases (RTKs) such as epidermal growth factor receptor (EGFR) whose activation is 
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crucial for vaccinia entry and this kinase may serve as an entry receptor. This induction 
activates complex signaling cascades leading to the initiation of these actin extensions 
which extend the plasma membrane allowing fluid-phase capture. This process involves 
signaling cascades that converge on members of the Ras superfamily of GTPases. 
Interestingly, multiple strains of vaccinia seem to enter HeLa cells by macropinocytosis, 
but the specific actin rearrangements and signaling requirements vary in different 
strains. While WR induces transient Rac1-dependent blebbing of the actin cytoskeleton, 
IDHJ induces filipodia formation dependent on Cdc42, suggesting multiple pathways of 
macropinocytosis exist and are exploited by different poxviruses [88,89]. Rac1 and 
Cdc42 contribute to a number of cellular processes that require extensive actin 
dynamics, and signaling is carefully regulated by several guanine exchange factors as 
well as by crosstalk with other Rho family GTPases [90,91,92]. Additional kinases such 
as Pak1 are then activated along with actin-associated proteins that ultimately lead to 
large-scale actin rearrangements, lipid modifications, and macropinosome formation 
[83,87]. While some specific kinase families have been implicated in macropinocytosis 
for both vaccinia strains (e.g., protein kinase C (PKC), serine/threonine kinases, tyrosine 
kinases, and phosphatidylinositol kinases) [87], many of the specific factors have not 
been identified, and in some cases the specific role of factors such as PKC, is not well 
understood. Chapter III will discuss a novel role for the host factor AMPK in vaccinia 
entry by macropinocytosis. 
4. Arboviruses 
Arthropod-borne viruses or Arboviruses include viruses that are transmitted by 
arthropod vectors, particularly biting insects. Arboviruses transit through at least two 
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hosts to complete their lifecycle. One host is a vertebrate, usually a bird or small 
mammal, and the second host is an arthropod vector, usually a mosquito. These viruses 
are maintained in an enzootic cycle with little mortality. However, if other hosts are 
infected, such as humans or livestock epizootic outbreaks can lead to high mortality. In 
some cases, the mortality occurs in dead-end hosts that cannont function as a reservoir 
for re-infection of mosquitoes, and generally do not transmit the virus to other hosts [10].  
The arboviruses infecting both humans and domestic animals have led to 
significant world-wide morbidity and mortality, and are both a medical and agricultural 
concern. Most arboviruses impacting human health fall into one of three viral families: 
Flaviviridae, Togaviridae, and Bunyaviridae.  Flaviviruses include medically important 
members such as Yellow Fever Virus, Dengue Virus, and West Nile Virus that are 
present in both temperate and tropical climates. West Nile Virus was originally identified 
in Africa, and until recently was limited to the Old World. However in 1999, there was an 
outbreak in New York that enabled the virus to spread across North America and into 
Central America and the Caribbean Islands [93,94]. The case of West Nile Virus 
demonstrates the potential ability of these arboviruses to spread to new geographical 
areas and why they represent a public health concern even in non-endemic areas. The 
Alphavirus genus within Togaviridae includes New World viruses that cause encephalitis 
in humans and equines, as well as Old World viruses that cause febrile and arthralgic 
illnesses, while Bunyaviridae includes members that cause haemorrhagic fever 
[95,96,97]. The Bunyavirus Rift Valley Fever Virus (RVFV) is the focus of Chapter IV. 
The Togavirus Sindbis and the Rhabdovirus Vesicular Stomatitis virus will also briefly be 
mentioned. 
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a. Rift Valley Fever Virus 
Bunyaviruses are arboviruses that include several disease causing members 
such as Sin Nombre, Hantavirus, Crimean-Congo hemorrhagic fever virus, and Rift 
Valley Fever virus (RVFV).  RVFV is a mosquito borne Category A agent initially 
endemic to sub-Saharan Africa. The virus was first identified in 1931 during an 
investigation of a sheep epidemic in the Rift Valley of Kenya. Since then, outbreaks have 
been reported in sub-Saharan and northern Africa, including a major outbreak in 1997-
98 in Kenya, Somalia, and Tanzania [98]. However, recent outbreaks of RVFV have 
occurred in Egypt and the Arabian Peninsula [99,100,101], indicating the potential of this 
virus to spread to new geographical areas, especially since a broad range of mosquito 
species have been linked to RVFV transmission [98].  
RVFV has particular importance as an agricultural pathogen, where infection of 
livestock can lead to significant morbidity and mortality, particularly among young 
animals. Infection leads to nearly 100% abortion among pregnant livestock, and over 
90% of infected lambs die from RVFV. However, mortality among adult sheep can be as 
low as 10% [98]. The majority of human infections result from direct or indirect contact 
with the blood or organs of infected animals, ingesting unpasteurized milk from an 
infected animal, or from mosquito transmission [98,102,103]. Most humans infected with 
RVFV develop a self-limited febrile illness with symptoms similar to meningitis, although 
approximately 1-3% die from the disease due to hemorrhagic symptoms, and in recent 
outbreaks the mortality rate in humans was reported to be as high as 45% 
[104,105,106,107,108]. The severity of RVFV zoonosis, along with its capacity to cause 
major epidemics among livestock and humans, and the lack of efficient prophylactic and 
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therapeutic measures make this pathogen a serious public health threat in endemic as 
well as non-endemic countries. RVFV is therefore classified as a BSL-3 or BSL3+/4 
agent in Europe and the U.S. respectively, and is considered a potential bioterrorist 
agent [107].  
Vaccines have been developed for veterinary use, including a live-attenuated 
vaccine MP-12, as well as inactivated virus vaccine [109,110,111]. The live vaccine 
provides long term immunity with only one dose, but can cause spontaneous abortion in 
pregnant animals, while the inactive vaccine requires multiple doses to provide 
protection, which may be problematic during outbreaks in endemic areas [112,113]. 
Moreover, vaccination during an outbreak is not recommended since it may actual 
intensify the outbreak. During mass animal vacciniation campaigns the use of multi-dose 
vials and the re-use of needles and syringes may allow further transmission of the virus 
throughout a herd. In humans, these vaccines can provide protective immunity; however, 
they are expensive to produce, and in the case of MP-12 may not be acceptable in areas 
where RVFV is not endemic [114,115]. No effective anti-viral therapies have yet been 
developed against RVFV.   
RVFV has a single-stranded tripartite genome that encodes six major proteins. 
The L and M segments have negative polarity, while the S segment is ambisense. The L 
segment encodes L, the viral RNA-dependent RNA polymerase. The M segment 
encodes two nonstructural proteins M segment-derived non-structural protein (NSm) of 
78 kDa (NSm1) and 14 kDa (NSm2), as well as the precursor of the two structural 
glycoproteins: Gn (glycoprotein located at the N-terminus of the precursor molecule), 
and Gc (glycoprotein located at the C-terminus of the precursor molecule) [116,117].  
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The S segment encodes two proteins. In the positive sense orientation S encodes S 
segment-derived non-structural protein (NSs), while in the negative sense orientation S 
encodes the nucleoprotein N [117].  The viral envelope is composed of a lipid bilayer 
containing the Gn and Gc glycoproteins that form regularly arranged surface subunits 
that cover the surface in a shell of 122 glycoprotein capsomers arranged in an 
icosahedral lattice [118,119,120]. The viral ribonucleoproteins are composed of the three 
genomic segments associated with numerous copies of N and L that are packaged in 
the virion through a strong interaction with the cytoplasmic tail of the glycoproteins 
[121,122]. The nonstructural proteins are dispensable for viral infection in cell culture, 
but play important roles in pathogenesis in vivo [123,124,125,126].  
The lifecycle of RVFV involves attachment and binding to as yet unidentified 
receptor, followed by membrane fusion and entry through a low-pH dependent 
mechanism mediated by the envelope glycoproteins and dependent on cellular PKCε 
[117,127,128].  The viral ribonucleocapsid is released into the cytoplasm and is 
transcribed into either mRNA for protein transcription or antigenomic cRNA for use in 
genome replication [117].  Replication occurs on modified perinuclear Golgi-derived 
tubular vesicle structures present in close association with mitochondria [129]. The 
cRNA present in the input virus serves as the template for synthesis of the NSs so that 
this virulence factor can be expressed immediately after the virus has entered the host 
cell [130].  Bunyaviral mRNA synthesis is initiated by a cap-snatching mechanism, where 
host mRNAs are cleaved through the endonuclease activity of the L protein to obtain 10-
18 nucleotide primers for transcription [131,132,133,134,135].  Synthesis of cRNA and 
vRNA does not require cap-snatching, and is initiated directly with 5’ nucleoside 
triphosphates. cRNA represents a complete copy of the viral genome, while mRNAs 
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terminate prior to the 5’ end of the template; however the mechanism of the switch 
between mRNA transcription and cRNA replication is unclear. The S and L segment 
mRNAs are transcribed on free ribosomes, while the M segment mRNA is translated on 
the rough ER [136,137]. The glycoproteins produced off of M are then cleaved from a 
common precursor molecule and migrate to the Golgi where they mature [137]. During 
assembly, the ribonucleocapsid, including N and L, associate with the glycoproteins and 
bud into the Golgi in vesicles [117].  Finally, these vesicles fuse with the plasma 
membrane allowing viral release.  
Little is known about the host factors that contribute to RVFV infection in insects 
or mammals, although the interferon-inducible MxA has been shown with virus like 
particles to inhibit RVFV transcription, and the RVFV NSs protein has been 
characterized as a major virulence factor to counteract the antiviral interferon system by 
suppressing interferon induction and inhibiting the interferon-inducible antiviral protein 
PKR [138,139,140,141].  Furthermore, mice incapable of mounting a robust type I 
interferon response to RVFV were more susceptible to infection, demonstrating the 
importance of innate immune defense in controlling this virus [142].  
b. Sindbis Virus 
Togaviruses are subdivided into two genera, the Alphaviruses and Rubiviruses 
[143]. In Chapter IV I will briefly discuss the role of AMPK in infection of the prototypical 
Alphavirus Sindbis. The Alphavirus group includes many medically and agriculturally 
important viruses including Eastern equine encephalitis virus, Western equine 
encephalitis virus, Venezuelan equine encephalitis virus, Ross River virus, and 
Chikungunya virus in addition to Sindbis [144]. Sindbis was first identified in 1952 in 
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Cairo, Egypt, and is most common in southern and eastern Africa, Egypt, Israel, 
Philippines, Australia, and northern Europe, making it the most widely distributed of the 
Alphaviruses that cause arthritis in humans [145]. The primary sites of Sindbis-mediated 
disease in humans are in northern Europe, where Sindbis causes Ockelbo, Pogosta 
fever, and Karelian fever in Sweden, Finland, and Russia respectively, and in South 
Africa. In other areas Sindbis causes a subclinical disease that manifests in fever, rash, 
or mild arthralgias. Sindbis Virus is transmitted by mosquito and maintained in nature by 
transmission between avian and mosquito vectors, with humans considered dead-end 
hosts [145].  
Alphaviruses are icosahedral enveloped arboviruses with a linear single-stranded 
positive sense RNA genome approximately 11.5 kb in length containing a 5’ methylated 
nucleotide cap and a 3’ polyadenylated tail that resembles cellular mRNA [144]. Sindbis 
encodes four nonstructural proteins involved in virus replication and pathogenesis, and 
five structural proteins that compose the virion [146]. The envelope consists of a host-
derived lipid bilayer embedded with 240 copies of E1 and E2 heterodimer glycoproteins 
further modified by palmitoylation, and smaller amounts of the K6 membrane-associated 
protein [146,147,148,149]. During entry, E2 is involved in receptor binding and 
subsequent clathrin-mediated endocytosis, while E1 is responsible for pH-dependent 
fusion of the viral membrane with the endosomal membrane [144]. The nucleocapsid 
enters the cytoplasm and dissociates allowing translation and genome replication. 
Replication occurs in cytopathic vacuoles derived from lysosomal and endosomal 
membranes [150]. Translation of genomic RNA yields two polyproteins: P123 or the 
larger P1234. The larger form occurs through translational readthrough of a termination 
codon that occurs 10-20% of the time. Thus the predominant product is P123 [151]. The 
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resultant polyproteins are cleaved by the virally encoded protease activity in the 
nonstructural protein nsP2 [152]. Both fully cleaved products and cleavage intermediates 
have been shown to play a role in virus replication [144]. After cleavage, structural 
proteins are translocated into the ER for processing and post-translational modifications 
that include the addition of high-mannose sugars and palmitoylation [153,154,155]. 
Proteins are then transported through the Golgi and to the plasma membrane where 
interactions between the nucleocapsid and glycoproteins occur, leading to virion 
assembly and ultimately budding from the plasma membrane [156,157,158].  A striking 
feature of alphavirus infection in vertebrate cells is the ability of the virus to shut down 
host transcription and translation without affecting viral synthesis. These shutdowns 
result in a decrease in type I interferon production, attenuating the innate immune 
response [144].   
c. Vesicular Stomatitis Virus 
The Rhabodovirus family includes Rabies virus, but the prototypical and best 
studied member is Vesicular Stomatitis Virus (VSV), which is discussed briefly in 
Chapter IV. VSV represents a widely studied prototype for the non-segmented, negative-
sense RNA viruses [159]. VSV infections cycle through cytolytic infection of mammalian 
hosts, particularly cattle, and persistent non-cytolytic infection and transmission by 
insects, such as sandflies. In cattle, horses, and pigs VSV produces a disease 
characterized by fever, and the formation of vesicles in the oral mucosa and teat, and is 
primarily of concern because it is similar in appearance to the catastrophic foot and 
mouth disease [159].   
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Rhadboviruses are rod or bullet shaped negative sense single stranded RNA 
viruses that typically encode 5 proteins: large protein (L), glycoprotein (G), nucleoprotein 
(N), phosphoprotein (P), and matrix protein (M) . The VSV-G envelope protein enables 
virus entry through pH-dependent clathrin-mediated endocytosis [160].  After low-pH 
fusion, the ribonucleocapsid is released into the cytoplasm, where it undergoes genome 
replication and protein synthesis. Viral P and L proteins comprise the core components 
of the viral RNA-dependent RNA polymerase, which is responsible for viral transcription 
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template for primary transcription by the virion RNA-dependent RNA polymerase, 
resulting in synthesis of leader RNA and all five monocistronic viral mRNAs that become 
processed to have a 5’ cap and a 3’ polyadenylated tail, and thus resemble cellular 
mRNAs that can be translated by ribosomes [159,161]. Viral proteins accumulate, 
leading to genome replication. A full-length positive strand RNA antigenome is 
synthesized and serves as the template for synthesis of progeny negative-strand 
genomes. The N protein encapsidates the RNA genome into a helical RNase-resistant 
core, while P acts as a chaperone to maintain the N protein in a soluble for in the 
cytoplasm before association with the genome [161]. The virus assembles by 
association of the ribonucleoprotein-matrix preassembly complexes with the G protein at 
the inner leaflet of the plasma membrane, and releases by budding from the plasma 
membrane [161].  
d. Lipid Metabolism in Arboviral Infection 
Lipid metabolism plays an important role in infection of many viruses that 
replicate in the cytoplasm including RVFV, Sindbis, and VSV.  An essential feature of 
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these infections is the ability of viruses to rearrange and proliferate internal cellular 
membranes into distinct invaginations or vesicle-like structures to compartmentalize the 
viral replication complex and support genome replication [162].  These membranous 
structures may serve to closely coordinate the replication complexes with virion 
assembly and budding, act as a scaffold for the replication complex to tether viral RNA, 
increase the local concentration of replication components, or prevent detection by the 
host immune defense system [162]. Depending on the virus, these membrane 
modifications can be derived from distinct cellular sources, including ER, Golgi, 
endosomal, and mitochondrial membranes, and may have complex biogenesis derived 
from multiple cellular origins [150,163,164,165,166,167,168,169,170]. Bunyavirus 
replication occurs on modified perinuclear Golgi-derived tubular vesicle structures 
present in close association with mitochondria, while Alphaviruses modify lysosomal and 
endosomal membranes into cytopathic vacuoles to support their replication complex and 
Rhabdoviruses use cytoplasmic inclusion bodies [129,150]. Despite these differences, 
there are many similarities in the membrane structures induced by different types of 
viruses suggesting commonalities in this induction across multiple virus families [171]. In 
some cases the viral proteins responsible for these changes are known, but host factors 
are also likely to contribute to this process. Importantly these modifications are highly 
dependent on cellular lipid biogenesis pathways and require generation of newly 
synthesized cellular lipids [162].  
5. Cellular Energy Metabolism 
Cellular energy metabolism is tightly regulated to allow organisms to balance 
energy requirements to maintain life. In order for growth and reproduction to occur, cells 
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and organisms must construct components such as proteins, lipids, and nucleic acids in 
anabolic processes that require the use of energy. In order to build these required 
components, energy must be harvested from the uptake and catabolic breakdown of 
energy-rich materials such as glucose, and stored in molecules such as ATP or GTP in a 
form the cell can use [172].  Energy is harvested and utilized in numerous complex 
cellular processes that must be carefully regulated so that energy consumption does not 
exceed availability. During the course of life, an organism or cell experiences many 
changes in energy demands and availability that can result from changes in activity 
level, or stresses such as glucose deprivation and starvation, hypoxia, ischemia, and 
oxidative or osmotic stress. Therefore, the success and survival of the cell depends on 
its ability to monitor cellular energy and respond to environmental stresses to maintain 
energy homeostasis.    
AMP-activated Kinase (AMPK) is an important regulator of cellular metabolism 
both on the cellular and organismal level. Once activated this complex switches the cell 
from an anabolic to a catabolic state by activating oxidative pathways that generate 
energy while inhibiting synthesis and growth pathways in order to return the cell to a 
state of energy homeostasis [173]. AMPK is conserved in all sequenced eukaryotes, and 
a null mutation results in embryonic lethality possibly due to developmental roles in 
establishing polarity [174,175]. AMPK is a heterotrimeric complex that consists of a 
catalytic alpha subunit as well as beta and gamma regulatory subunits [173]. Drosophila 
encode only one gene for each subunit whereas more redundancy is seen in 
mammalian systems with multiple isoforms of each subunit encoded by several distinct 
genes (α1, α2, β1, β2, γ1, γ2, γ3) that can produce at least 12 possible heterotrimeric 
combinations [176]. In mice, no phenotype is associated with deletion of the α1 gene, 
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while deletion of the α2 is associated with metabolic phenotypes, indicating partial 
functional redundancy of the two catalytic subunits [177,178,179]. While expression 
patterns of individual subunits vary, the precise function of each subunit combination 
remains unclear.  
AMPK is activated in response to an increase in cellular AMP or ADP compared 
to ATP [173,180]. Bateman domains of the regulatory gamma subunit are exchangeable 
competitive binding sites for AMP, ADP, or ATP. Activation is triggered through binding 
of AMP or ADP to these binding sites, leading to increased phosphorylation of the 
threonine 172 on the alpha subunit [180,181,182]. Binding of two AMP inhibits 
dephosphorylation of AMPK and also promotes additional allosteric activation, while tight 
binding of a single ADP protects AMPK from dephosphorylation without allosteric 
activation [180,182,183]. Evidence suggests that AMPK may be most strongly regulated 
by dephosphorylation [183,184]. The canonical upstream activator of AMPK that 
catalyzes this phosphorylation event is the constitutively active tumor suppressor LKB1 
[185,186]. Other upstream activators have also been identified that may function 
independently of energy levels. Calmodulin-dependent protein kinase kinase beta 
(CaMKKβ) has been reported to phosphorylate AMPK on the Thr172 in a calcium-
dependent manner [187,188]. Additional upstream activators have been identified in 
yeast. In addition to Tos3p, the yeast homolog of LKB1, Sak1 and Elm1p have been 
shown to activate AMPK in vivo and in vitro in yeast, suggesting the possibility of 
additional activators in other systems as well [189].  Finally, TGFβ-activated kinase 
(TAK1) has also been implicated to activate both yeast and mammalian AMPK in 
overexpression studies [190]. AMPK activation by TAK1 has been shown to induce 
autophagy, which has been implicated in innate immunity [191,192]. While unclear if this 
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activation is relevant in vivo, TAK1 is involved in innate immune signaling, and may 
provide a link between AMPK signaling and innate immune defense [193,194,195,196].  
In addition to cellular control, AMPK is also regulated by cytokines that control 
whole-body energy balance, such as leptin, adiponectin, ghrelin, cannabinoids, 
interleukin-6, and ciliary neurotrophic factor (CNTF) [176,197,198]. In particular, AMPK 
is regulated by cytokines released by adipocytes including leptin, adiponectin, and 
resistin. These cytokines can have different effects on different tissues. In skeletal 
muscle, AMPK activation by leptin and adiponectin increased glucose uptake and fatty 
acid oxidation. In the liver, adiponectin stimulates fatty acid oxidation and inhibits 
glucose production, while resistin has the opposite effect [176]. AMPK activation in the 
brain may regulate food intake. In mice, activation of AMPK in the hypothalamus 
stimulates food intake, while treatment with anorexigenic agents such as insulin inhibit 
AMPK and lead to a repression of food intake even in fasted mice [199]. Thus in addition 
to regulating cellular energy, AMPK is an important regulator of whole-body energy 
balance, linking it to obesity through food intake and energy expenditure [200].  
6. Downstream Functions of AMPK 
AMPK activation stimulates ATP-producing catabolic pathways, while inhibiting 
ATP-consuming anabolic pathways rapidly through phosphorylation, and also more 
slowly through transcriptional regulation [173]. This activation has a number of important 
downstream effects. AMPK activation increases translocation of the glucose transporter 
GLUT4 to the plasma membrane, thus stimulating glucose uptake in a manner 
somewhat redundant with insulin activation of Akt signaling [201,202,203]. At the same 
time, activity and expression of many biosynthetic genes and pathways are 
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downregulated by AMPK. These include protein targets involved in lipid metabolism, 
carbohydrate metabolism, protein metabolism, and transcription. AMPK activation also 
has effects on cell signaling, ion transport, and polarity given this complex control over 
many aspects of cell biology [173]. Several of the downstream effectors of AMPK target 
mechanisms important for viral infection, and are further discussed below.  
 a. AMPK Regulation of Protein Synthesis 
AMPK activity inhibits global protein translation by multiple signaling mechanisms 
(Figure 1A). AMPK inhibits the mTOR Complex 1 (mTORC1) which is an important 
activator of protein synthesis through two main downstream effectors [204]. mTORC1 
phosphorylates p70-S6 Kinase 1 (S6K1) on multiple residues with the most critical 
modification occurring on the Thr-389 [205,206]. This phosphorylation event stimulates 
the phosphorylation and activation of S6K1. S6K1 activates the 40 S ribosomal protein 
S6 and other components of the translation machinery, leading to increased translation 
initiation [207]. Additionally, mTORC1 has been shown to phosphorylate at least four 
residues of 4E-BP1 in a hierarchical manner [208]. In a non-phosphorylated state, 4E-
BP1 inhibits the translation initiation factor eIF4E by tightly binding it and preventing it 
from binding to 5’capped mRNAs and recruiting them to the ribosomal initiation complex. 
Phosphorylation of 4E-BP1 by mTORC1 releases this binding and allows eIF4E activity, 
thus promoting translation initiation [208].  
mTORC1 is regulated by the upstream tuberous sclerosis complex (TSC) that 
receives inputs from multiple upstream signaling pathways, including AMPK [204,209]. 
These kinase-mediated signaling pathways alter the ability of TSC1/TSC2 to function as 
a GTPase activating protein (GAP) towards Rheb, the major regulator of mTORC1 
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[210,211,212,213,214]. Rheb is active in its GTP-bound form, and is then able to 
activate mTORC1. TSC1/TSC2 activity therefore inhibits the activity of Rheb in 
unstimulated conditions [209]. Several pathways are able to alter the activity of 
TSC1/TSC2. AMPK phosphorylates TSC2 at 2 sites (Ser 1270 and Ser 1388) which 
enhances the ability of the TSC1/TSC2 complex to act as a GAP, and blocks Rheb-
dependent mTORC1 activation leading to an inhibiton of protein synthesis [215]. In 
contrast, Akt is another major regulator of the mTORC1 pathway that becomes activated 
in response to growth factors such as insulin [216,217]. Akt phosphorylates TSC2 on at 
least five sites distinct from those targeted by AMPK, inhibiting the activity of TSC2 and 
thus activating mTORC1 and protein synthesis [209]. Finally TSC1 can also be 
phosphorylated at distinct sites by members of the MAPK pathway to inhibit TSC1/TSC2 
activity, and thus activate mTORC1 [218,219]. Therefore, regulation of protein synthesis 
downstream of mTORC1 is complex, and while AMPK is an important regulator, other 
upstream pathways also contribute to regulating translation initiation. 
  In addition to regulating translation initiation through mTORC1, AMPK also 
regulates translation elongation through Elongation Factor 2 (eEF2) [220,221]. eEF2 is 
the phosphoprotein that mediates the translocation step of peptide chain elongation 
during protein translation [222]. Phosphorylation at the Thr-56 residue inactives the 
protein by preventing ribosome binding [223,224]. This phosphorylation event is 
catalyzed by the calcium/calmodulin-dependent protein kinase eEF2 kinase, which, like 
mTORC1, can be regulated through multiple upstream pathways [222]. AMPK directly 
phosphorylates eEF2 kinase on several serine residues, with Ser-398 being its major 
target [221]. This phosphorylation stimulates eEF2K activity, which inhibits eEF2 and 
elongation.  In contrast, eEF2K is inactivated by phosphorylation at Ser-366 by S6K 
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downstream of mTORC1 or by p90RSK, resulting in increased translation [225].  
Likewise phosphorylation by p38 MAPK inhibits eEF2K activity [226].  Therefore, protein 
synthesis mediated by both mTORC1 and eEF2 are regulated by multiple pathways with 
considerable crosstalk, and other signaling events besides AMPK may contribute to 
regulation of protein synthesis during viral infection.  
b. AMPK Regulation of Autophagy 
Autophagy is a catabolic process by which cells break down their own 
components by engulfing a portion of the cytoplasm in an isolation membrane, and then 
delivering the contents to lysosomes for degradation [192]. This process is an important 
repair mechanism for degrading damaged organelles, membranes, and proteins, and 
contributes to survival during periods of nutrient starvation by recycling non-vital 
components [227]. Evidence also suggests that autophagy is involved in innate immune 
defense through destruction of intercellular pathogens, and plays a crucial role in 
resistance to bacterial, viral, and protozoan infections [192].Like protein synthesis, 
autophagy is dually regulated by AMPK and Akt downstream of mTORC1 [227]. 
Activation of mTORC1 leads to inhibition of autophagy. Therefore, since AMPK activity 
leads to a decrease in mTORC1 activity as described above, AMPK activation is 
associated with a cooresponding increase in autophagy, while Akt activity leads to an 
increase in mTORC1 activity and decreased autophagy (Figure 1A). Thus AMPK activity 
could interefere with viral infection through autophagy mediated restriction.   
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c. AMPK Regulation of Fatty Acid Synthesis 
AMPK is an important regulator of lipid metabolism, inhibiting both sterol and 
fatty acid synthesis, while promoting fatty acid oxidation (Figure 1B) [228]. 
Phosphorylation downstream of AMPK inactivates acetyl CoA carboxylase (ACC), a 
rate-limiting enzyme in fatty acid metabolism [229,230]. ACC catalyzes the irreversible 
conversion of acetyl-CoA to malonyl-CoA, the substrate for fatty acid synthesis, which 
drives de novo production of palmitate [231]. In addition to this important role in fatty acid 
synthesis, malonyl-CoA is a cosubstrate for the fatty acid elongation system located in 
the membrane of the endoplasmic reticulum [232]. This system allows chain lengthening 
of both endogenously synthesized and dietary-derived essential fatty acids into higher 
polyunsaturated fatty acids. Finally, malonyl-CoA serves a signaling function through 
inhibition of carnitine palmitoyltransferase I (CPT-1), an essential factor involved in the 
transport of fatty acids to the mitochondria for beta oxidation [231]. Thus malonyl-CoA 
production by ACC promotes fatty acid synthesis, while inhibiting fatty acid oxidation.  
Mammalian systems encode two non-redundant ACC isoforms, ACC1 and ACC2, which 
are both targeted by AMPK for phosphorylation and inactivation [228]. In vitro studies 
revealed that AMPK could phosphorylate ACC1 on multiple serine residues, but 
phosphorylation of Ser79 occurs most rapidly, and is associated with inactivation 
[229,230,233]. While other protein kinases have been shown to phosphorylate ACC1 in 
vitro, evidence of physiological relevance exists only for AMPK [229,234].  Studies 
suggest that malonyl-CoA produced by ACC2 is exclusively involved in fatty acid 
oxidation, while ACC1 contributes to fatty acid synthesis [228].  Therefore, activation of 
AMPK through stress or low energy conditions induces fatty acid oxidation through 
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ACC2, while inhibiting fatty acid synthesis through ACC1 and could impact the ability of 
viruses to subvert lipid metabolism for their replication.  
d. AMPK Regulation of the Cytoskeleton       
While the best understood role of AMPK is its role in metabolism, recent 
evidence suggests this kinase also has a crucial role in regulating cell structure and 
polarity through engagement with the actin cytoskeleton [235]. In Drosophila, loss of 
AMPK leads to defects in mitotic division and epithelial cell polarity accompanied by 
disruption of the actin cytoskeleton [175]. In some mammalian epithelial cell lines, AMPK 
activation leads to polarization characterized by the formation of an actin brush-border or 
tight junction assembly [175,236,237,238]. Additionally, AMPK activation can induce 
astrocyte stellation, and actin stress fiber disassembly [239], and studies using 
Compound C and AMPK activators have linked AMPK to macropinocytic uptake of 
albumin in murine macrophages [240]. Finally, recent evidence suggests that AMPK 
regulates microtubules as well as actin. AMPK  phosphorylates the microtubule plus end 
protein CLIP-170, and knock down of AMPK impairs microtubule stabilization and 
directional cell migration [241]. I provide further evidence in Chapter III that AMPK is 
crucial in promoting actin-driven macropinocytosis and membrane ruffling as well as cell 
migration, and this modulation of the actin cytoskeleton is important in promoting 
vaccinia entry. This accumulating evidence suggests a broad and conserved role for 
AMPK in a variety of cellular processes that require cytoskeletal rearrangements.  
The precise signaling events that lead to these AMPK-dependent cytoskeletal 
changes remain unclear. Several upstream kinases have been shown to activate AMPK 
under different stimuli. The best studied of these is the tumor suppressor LKB1 which 
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activates AMPK in response to changes in cellular energy levels [185,186]. Additionally, 
AMPK can be activated in response to changes in intracellular calcium levels by 
CaMKKβ, and further evidence suggests that TGFβ-activating kinase (TAK1) may serve 
as a third upstream activator [187,188,190]. Previous studies demonstrated that LKB1 is 
an important mediator of cell polarity at least in part through signaling to AMPK, and has 
been shown to drive actin brush border formation, and the translocation of apical and 
basal markers during the establishment of polarity [175,236,237,242,243], but how this 
process is fine-tuned and regulated in a physiologically relevant context remains to be 
determined.   
7. The Role of AMPK in Metabolic Diseases 
Since AMPK is an important regulator of energy metabolism, it has been 
implicated in type II diabetes, obesity, and related metabolic diseases [244,245]. AMPK 
activation has pleiotrophic effects in a number of metabolically relevant tissues, such as 
liver, skeletal muscle, adipose, and hypothalamus [245]. During type II diabetes, liver, 
skeletal muscle, and adipose tissue can become insulin resistant. This state of insulin 
resistance leads to a dramatic decrease in glucose uptake and utilization, reduced 
mitochondrial capacity, and defects in fatty acid oxidation that can ultimately interfere in 
the ability of skeletal muscle to switch between glucose and fatty acid metabolism [246]. 
AMPK activation is able to counteract some of the effects of insulin resistance. Notably, 
many of the metabolic changes induced by AMPK would be desirable in the treatment of 
type II diabetes and metabolic syndrome. These changes include increased glucose 
uptake and mitochondrial biogenesis, increased fatty acid oxidation in muscle and liver, 
and decreased fatty acid synthesis in liver and adipose tissue 
29 
 
[247,248,249,250,251,252,253].  Indeed, drugs that activate AMPK have been shown in 
rats and humans to alleviate some of the metabolic symptoms associated with diabetes 
[254,255,256,257,258,259,260,261,262].  
 Two classes of drugs used clinically to treat type II diabetes activate AMPK, and 
may function at least in part through this mechanism. One class of AMPK activating anti-
diabetic drugs is the biguanides, including Metformin and Phenformin. Metformin has 
been in use since 1957 and is the most widely used drug to treat type II diabetes. 
However, it is a low-potency compound that is used at high doses with only moderate 
efficacy and can have significant side effects. It reduces hyperglycermia without 
stimulating insulin secretion, promoting weight gain, or causing hypoglycermia [263,264]. 
Decreased hepatic glucose production and increased skeletal myocyte glucose uptake 
are believed to be major contributors to Metformin’s glucose lowering effects, and likely 
results from the AMPK activating effects of drug treatment [258,263,265,266,267]. 
Metformin activates AMPK indirectly, and likely has additional cellular targets [262,268]. 
For example, studies indicate that Metformin inhibits mTORC1 independent of AMPK 
and reduces circulating levels of insulin and insulin-like growth factor [269].     
 In addition to treatment of type II diabetes, AMPK activation may have other 
beneficial effects on health. AMPK has been linked to longevity in model organisms such 
as flies and worms, and may contribute to the beneficial effects of exercise [270,271]. 
AMPK activation also inhibits cell proliferation and a growing body of evidence suggests 
that AMPK activating drugs such as Metformin can reduce the risk of cancer 
[272,273,274,275]. An observational study in 2005 found that diabetics taking Metformin 
had a 40% lower risk of a variety of cancers than those taking other diabetic drugs [276]. 
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In a mouse model of lung cancer, mice given Metformin orally or by injection had a 
reduction in the number and size of tumors [277]. Finally, since AMPK activating drugs 
are already on the drug market, they may also provide useful therapeutics against 
certain viral infections. In Chapter IV I discuss the role of AMPK activation in control of 
RNA virus infection. Metformin has already been tested in several clinical trials for the 
treatment of Hepatitis C Virus (HCV). Two small trials with Pioglitazone had inconsistent 
results, while a larger trial using metformin showed significant improvement in sustained 
virological response particularly among females [278,279,280]. In Chapter IV I provide 
evidence that AMPK activation is more broadly anti-viral among disparate RNA viruses, 
and therefore these AMPK activating drugs may make promising anti-viral therapeutics 
against multiple infections.  
8. Aims of Present Studies 
Host interactions play an integral role in determining the outcome of viral 
infection. These interactions can be required for the virus to complete certain stages of 
its lifecycle, or can restrict viral infection as part of an innate immune response program. 
Since viral pathogens represent a significant threat both medically and agriculturally, a 
better understanding of both types of host interactions could facilitate the treatment of 
viral infections and provide novel targets for therapeutics. Host factors that are required 
for infection could be targeted with inhibitory molecules to block the virus lifecycle and 
prevent replication, while host processes that contribute to viral restriction could be 
enhanced to further assist the innate immune response in controlling infection. Therefore 
the work described in Chapters III and IV aims to investigate the role of cellular 
metabolic signaling in viral infection. Cellular metabolic signaling is mediated through 
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AMPK, the central sensor of cellular energy levels. In response to various types of 
cellular stress centering on low energy conditions, AMPK is activated and induces 
changes in numerous downstream pathways, many of which are likely to be involved in 
viral infection.  
 In Chapter III I describe an RNAi screen of Drosophila kinases and phosphatases 
that led to the identification of AMPK as a novel host factor that contributes to infection of 
the Poxvirus vaccinia. In mammalian cells AMPK contributes to vaccinia infection by 
facilitating entry through macropinocytosis, and importantly, AMPK contributes to other 
cell biological processes that depend on rearrangements of the actin cytoskeleton. This 
role of AMPK in cytoskeletal rearrangements has only recently been discovered, and it is 
likely that other novel players upstream and downstream of AMPK also contribute to this 
process and have yet to be identified.  
 Macropinocytosis is a specific actin-dependent route that a subset of viruses 
employ for entry. I have shown in Chapter III that the requirement for AMPK during entry 
is specific to poxviruses. During these studies, I found a number of RNA viruses, in 
particular Rift Valley Fever Virus (RVFV), that are actually restricted by AMPK, as 
discussed in Chapter IV. RNA viruses rearrange and proliferate internal cellular 
membranes into distinct invaginations or vesicle-like structures to compartmentalize the 
viral replication complex and support genome replication. AMPK is a potent inhibitor of 
fatty acid synthesis required for these membrane proliferations, and restricts RVFV 
through this mechanism. AMPK activation reduces levels of cellular lipids, while 
exogenous addition of the fatty acid palmitate restores RVFV infection by bypassing fatty 
acid synthesis. Since additional viruses such as VSV and Sindbis are also restricted by 
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AMPK, this mechanism may be broadly anti-viral. Furthermore, since AMPK-activating 
drugs are currently in use for treatment of type II diabetes, I postulate that they may also 
be useful therapeutics against a broad range of viral infections. Taken together, AMPK 
represents a host factor that can have either pro-viral or anti-viral effects depending on 
the specific life cycle requirements of each virus, and as such may represent a useful 
drug target. 
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Figure 1.1: AMPK regulates protein and lipid metabolism.  A. AMPK inhibits protein synthesis 
by dually inhibiting activity of mTORC1 and eEF2. mTORC1 induces translation initiation through 
4E‐BP1 and S6K1, and also inhibits autophagy.  Phosphorylation of eEF2 by eEF2K inhibits its 
activity in translation elongation. B. AMPK is a key regulator of lipid metabolism, inhibiting fatty 
acid and sterol synthesis while promoting fatty acid oxidation.  
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II. MATERIALS AND METHODS 
1. Cells, Antibodies, Reagents, and Viruses 
 Drosophila DL1 cells were grown and maintained at 25°C in Schneiders 
Drosophila media supplemented with 10% FBS (JRH) as described [7]. MEFs, BSC-1, 
BHK and U2OS cells were maintained at 37°C in DMEM supplemented with 10% FBS 
(Sigma) and 10mM Hepes. HeLa S3 suspension cells were maintained in MEM 
supplemented with 10% FBS and 0.05% Pluronic.  BSC-1 cells were maintained in MEM 
supplemented with 10% cosmic calf serum (Hyclone).  All media were additionally 
supplemented with 100 ug/ml penicillin/streptomycin and 2 mM L-glutamine. LKB1-/- 
MEFs were complemented with MIGR (Vector) or FLAG-LKB1-MIGR (LKB1 cDNA) and 
maintained as above.  
Vaccinia strains vPRA13, vSC8, and vP30CP77, were grown in HeLa S3 
suspension cells supplemented with 2.5% FBS, and titered on BSC-1 cells as described 
[281,282,283,284]. Cowpox Brighton Red, Vesicular Stomatitis virus (Indiana), Rift 
Valley Fever Virus MP-12 and Sindbis Virus were used. Antibodies were obtained from 
the following sources: anti-Bgal (Promega and Cappel), anti-E3L (gift from S. Isaacs) 
[285], anti-L1R (R180 gift from G. Cohen and R. Eisenberg), anti-RVFV ID8, anti-Rac1 
(Millipore),and anti-P-AMPK, t-AMPK, P-ACC, t-ACC, P-eEF2, t-eEF2 (Cell Signaling 
Technology).  Fluorescently labeled secondary antibodies along with anti-sheep HRP 
were obtained from Jackson Immunochemicals or Invitrogen. All other HRP-conjugated 
antibodies were obtained from Amersham. AlexaFluor 488 and 594 phalloidin, FITC-
conjugated dextran, and 594-conjugated Transferrin and BODIPY-TR were purchased 
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from Invitrogen.  Compound C [258] and STO-609 [286] were obtained from 
Calbiochem. Additional chemicals were obtained from Sigma.   
2. RNAi and Infections  
 A mini library of dsRNAs generated against Drosophila kinase and phosphatase 
genes was obtained from N. Perrimon, and aliquoted onto 384 well plates at 250ng 
dsRNA/384 well [287]. Secondary amplicons and control dsRNA were designed using 
SnapDragon and DRSC resources (www.flyrnai.org), and generated as described [288]. 
RNAi was performed as described [289]. Briefly, for 384 well assays, 16,000 DL1 cells 
were seeded onto 250ng dsRNA in 10ul serum free media. One hour later 20ul complete 
media was added, and cells were incubated in a humid chamber for 3 days. For other 
experiments, 2,000,000 cells were seeded onto 4ug of dsRNA/6 well in 1mL serum free 
media. One hour later 2 mL complete media was added. For viral infections, vaccinia 
was titered on BSC-1 cells, and MOIs added to all cell types are based on pfu/ml 
measured on BSC-1 cells. All other viruses were tittered on BHK cells. Media was 
removed and virus was added in 2% serum medium and incubated at 25°C for 
Drosophila cells, and 37°C for mammalian cells. For RVFV, Sindbis, and VSV, cells 
were spinoculated for 1 hour at 1200 RPM for 1 hour prior to incubation. Viral innocula 
used was adjusted to achieve ~10% infection of Drosophila cells in the primary screen, 
and ~20% infection in secondary analysis. Level of infection of mammalian cells varied 
depending on the assay format and was optimized through viral serial dilutions. Cells 
were processed at the indicated time point post infection. 
 
 
36 
 
3. siRNA 
siRNAs were obtained from ABI. U2OS cells were reverse transefected with 
HiPerfect and incubated for 3 days followed by infection at MOI=10 for 8 hours, fixed, 
and processed for immunofluorescence.   
4. Viral Immunofluorescence 
 Cells were fixed and processed for immunofluorescence as previously described 
at 48 hours post infection for Drosophila cells and 8 hours post infection in mammalian 
cells for vaccinia, and 10 hours post infection for RVFV, Sindbis, and VSV [8]. Briefly, 
cells were fixed in 4% formaldehyde/PBS, washed twice in PBS/0.1% TritonX-100 
(PBST), and blocked in 2% BSA/PBST. Primary antibodies were diluted in block, added 
to cells, and incubated overnight at 4ºC. Vaccinia was stained with anti-E3L and anti-B-
gal. RVFV was stained with anti-RVFV ID8. VSV and Sindbis expressed GFP, and did 
not require antibody staining. Cells were washed three times in PBST, and incubated in 
secondary antibody for one hour at room temperature. Cells were counterstained with 
Hoescht33342 (Sigma). Plates were imaged at 20X for Drosophila cells and 10X for 
mammalian cells, capturing three images per well per wavelength using an automated 
microscope (ImageXpress Micro), and quantification was performed using MetaXpress 
image analysis software. Significance was determined using a Student T-test.  
5. Screen Analysis 
 Image analysis was used to generate metrics from the captured images including 
the number of nuclei and the number of infected cells per site. The percent infection was 
calculated for each site, log-transformed, and the interquartile range (IQR) was used to 
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calculate a robust Z score for each site using the following equation: log10 [(%infection-
median)/(IQR*0.74)] [290]. Candidates were identified as positive if the average robust Z 
score of all sites in a well was <-2 in two independent replicates.   
6. Immunoblotting, Northern blotting, and RT-PCR 
 For protein analysis, MEFs were prechilled to 16°C for 10 minutes and then 
treated with vaccinia (MOI 20) for 1 hour at 16°C to synchronize infection. Cells were 
incubated at 37°C for 10 or 30 minutes or treated with 10uM 2DG for 30 minutes. To 
analyze downstream effectors of AMPK, MEFs were treated with 12 mM 2DG, 10 uM 
oligomycin, or 100uM A769662 for 4 hours. Cells were then washed briefly in cold PBS 
and lysed in NP40 lysis buffer supplemented with protease (Boehringer) and 
phosphatase (Sigma) inhibitor cocktails. Samples were separated by SDS-PAGE and 
blotted as described [170]. HRP-conjugated secondary antibodies and Western 
Lightening Chemiluminescence Reagent were used for visualization.  
For RNA analysis, cells were lysed in Trizol buffer, and RNA was purified and 
blotted as previously described with the indicated probes [8]. RT-PCR was performed 
using M-MLV reverse transcriptase on random primed total RNA (Invitrogen). One uL of 
the cDNA or a 1:10 dilution was used for PCR amplification.  
7. Plaque Assays 
 Viruses were plaqued on MEF or BSC-1 cells as indicated. Confluent monolayers 
were treated with serial dilutions of virus for two hours, after which the cells were 
overlayed with agarose, and incubated at 37°C for 48 hours. Cells were fixed in 10% 
formaldehyde, followed by crystal violet staining. Plaque number was determined 
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manually, and plaque diameter was measured using MetaXpress software and used to 
calculate areas. 
8. Vaccinia Entry Assay 
 MEFs plated on coverslips were chilled to 16°C for 10 minutes and then treated 
with vaccinia (MOI 100) at 16°C for 1 hour. Unbound virus was removed, and cells were 
incubated at 37°C for 1 hour, washed three times in cold PBS, and fixed. Cells were 
washed in ammonium chloride (50mM) and PBST and were stained with anti-L1R and 
then washed and incubated with secondary antibody, Hoescht 33342, and phalloidin 
488. Coverslips were mounted and imaged using using a 63X objective with a Leica DMI 
4000 B fluorescent microscope. Images were taken as 0.2 um z-stacks that were 
deconvolved using AutoQuant X2 software using Adaptive PSF with 20 iterations. 
Images are displayed as max projections. To quantify, images were randomized and 
blindly quantified for virus entry (n>30 for each condition). 
9. Fluid Phase Dextran Uptake Assay 
 MEFs grown on glass coverslips were chilled to 16ºC for 10 minutes and then 
treated with vaccinia (MOI=200) at 16º C for 1 hour. Unbound virus was removed, and 
FITC-dextran (70kD, lysine fixable) was added at 0.5 mg/ml. Cells were incubated at 37º 
C for 20 minutes, washed twice in PBS, and once in pH 5.5 buffer (0.1 M sodium 
acetate, 0.05 M NaCl) for 5 minutes. Cells were fixed and stained with Hoescht 33342 
and phalloidin 594. Coverslips were mounted and imaged using a 63X objective with a 
Leica DMI 4000 B fluorescent microscope. Images were randomized and blindly 
quantified for the percentage of cells undergoing macropinocytosis as defined by >20 
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puncate per cell. U2OS cells grown on glass coverslips were pretreated with 10uM 
Compound C or vehicle for 1 hour and then assayed as above.  
10. Actin Ruffling Assay 
 Cells were grown on glass coverslips and treated with vehicle or 1 uM PMA for 3 
hours. For Rac1 localization experiments, cells were blocked in 8% BSA/PBST for 1 
hour. Anti-Rac1 (Millipore) was added in 1% BSA/PBST overnight at 4ºC Cells were 
washed 3 times in PBST, and secondary antibodies were added for 1 hour at room 
temperature. For all experiments, cells were stained with Hoescht 33342 and phalloidin 
488. Coverslips were mounted and imaged using a 63X objective with a Leica DMI 4000 
B fluorescent microscope. 
11. Transferrin Uptake Assay 
Cells grown on glass coverslips were chilled to 16ºC for 10 minutes and then 
treated with vaccinia (MOI=100) at 16º C for 1 hour. Unbound virus was removed, and 
594-transferrin was added at 20 ug/ml. Cells were incubated at 37º C for 20 minutes, 
washed twice in PBS, and once in pH 5.5 buffer (0.1 M sodium acetate, 0.05 M NaCl) for 
5 minutes. Cells were fixed and stained with Hoescht 33342 and phalloidin 488. 
Coverslips were mounted and imaged using a 63X objective with a Leica DMI 4000 B 
fluorescent microscope.  
12. Wound Healing Assay 
Cells were grown to 100% confluence overnight, then scratched with a pipet tip to 
wound. Several marks were made along the length of the wound, and were imaged over 
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time, using these marks as guides. Images were analyzed for wound length at the same 
position over time using MetaXpress software.  
13. Cellular Lipid Staining  
Cellular lipids were stained as previously described [291,292]. MEFs were grown to 
confluence overnight, and then treated with PBS vehicle or 100uM A769662 for 10 
hours. Cells were fixed in 4% formaldehyde for 10 minutes and washed three times in 
PBS. Staining was performed with 10 ug/ml BODIPY-TR and counterstained with 
Hoescht33342 in 100mM glycine in PBS overnight. Cells were washed three times in 
PBS and imaged using the ImageXpress Micro automated microscope.   
14. Fatty Acid Synthesis Bypass Assay 
Exogenous palmitate addition was performed as previously described [293]. 
Delipidated Fetal Calf Serum and Albumin-bound palmitate were prepared as described 
[293] and obtained as a kind gift from Robert Rawson. U2OS cells were set up on day 0 
in 96 well plates and grown over night in normal growth medium. On day 1 medium was 
removed and cells were washed briefly in PBS. Cells were refed with low glucose DMEM 
supplemented with 5% delipidated Fetal Calf Serum with or without 100uM Albumin-
bound palmitate, and incubated overnight. On day 2 cells were treated with 100 uM 
A769662 or PBS vehicle for 1 hour, and infected with RVFV  Plates were shaken for 5 
minutes, spinoculated for 1 hour at 1200 RPM, and incubated for 10 hours to allow 
infection. Cells were fixed in 4% formaldehyde, stained with antibodies, and imaged at 
10 X using the automated microscope ImageXpress Micro, as described above. 
Quantification was performed using MetaXpress image analysis software. Significance 
was determined using a Student T-test.  
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 III. A KINOME RNAI SCREEN IDENTIFIED AMPK AS PROMOTING POXVIRUS 
ENTRY THROUGH THE CONTROL OF ACTIN DYNAMICS1 
1. Introduction 
 In order to successfully infect cells, viruses must remodel the cellular 
environment to allow for the reallocation of resources to viral production. Poxviruses are 
large dsDNA viruses that have a sophisticated lifecycle characterized by a number of 
temporally regulated steps. Vaccinia virus is the prototypical poxvirus, was used as the 
vaccine to eradicate smallpox, and has been the most thoroughly characterized [11]. To 
initiate infection, vaccinia first binds, enters cells, uncoats, and expresses early gene 
products. Next, genomic DNA replication occurs, followed by intermediate and late gene 
expression. Assembly, maturation, and virus release completes the cycle. Although 
poxviruses encode a large number of genes (>200), they remain obligate intracellular 
pathogens and require a multitude of activities hijacked from their host cell. While many 
viral factors required for various steps in the vaccinia lifecycle have been described, the 
specific host factor contribution is less clear.  
In particular, an early step in the infection cycle involves cell penetration. This 
step is critical for the initial establishment of infection, and also presents a good target 
for anti-viral therapeutics [294]. Different families of viruses have developed diverse 
strategies for entering cells; some fuse at the plasma membrane, while others co-opt 
 
1. This chapter was reprinted from Moser TS, Jones RG, Thompson CB, Coyne CB, 
Cherry S, 2010 A Kinome RNAi Screen Identified AMPK as Promoting Poxvirus Entry 
through the Control of Actin Dynamics. PLoS Pathog 6(6): e1000954. 
doi:10.1371/journal.ppat.1000954 
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one of the many cellular endocytic routes [58]. Studies have demonstrated that 
macropinocytosis is an important endocytic route of vaccinia entry [83]. Generally, 
macropinocytosis is a nonselective route for bulk fluid-phase uptake and is not 
constitutively active, but is induced by growth factors, and also by some pathogens 
including vaccinia [87,88]. This active endocytic process induces extensive actin 
cytoskeletal rearrangement, leading to membrane ruffling, lamellipodia formation, and 
the internalization of extracellular fluid and membrane. Consistent with this, vaccinia 
entry is dependent upon modulation of the actin cytoskeleton, and initiates 
macropinocytosis by inducing dramatic actin-rich microvilli protrusions followed by global 
myosin II-dependent blebbing, thereby promoting virus uptake [78,83]. Induction triggers 
the activation of receptor tyrosine kinases (RTKs) which activate complex signaling 
cascades leading to the induction of these actin extensions which extend the plasma 
membrane allowing fluid-phase capture. This process involves signaling cascades that 
converge on members of the Ras superfamily of GTPases in particular, Rab5 and Rac1 
[88,89]. Rac1 contributes to a number of cellular processes that require extensive actin 
dynamics, and its signaling is carefully regulated by several guanine exchange factors 
as well as by crosstalk with other Rho family GTPases [90,91,92]. Again, as for growth 
factor dependent macropinocytosis, vaccinia-induced uptake is dependent upon Rac1 
[78,83]. Additional kinases such as Pak1 are then activated along with actin-associated 
proteins that ultimately lead to large-scale actin rearrangements, lipid modifications, and 
ultimately macropinosome formation [83,87]. While some specific kinase families have 
been implicated in macropinocytosis (e.g., protein kinase C (PKC), serine/threonine 
kinases, tyrosine kinases, and phosphatidylinositol kinases) [87], many of the specific 
factors have not been identified, and in some cases the specific role of factors such as 
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PKC, is not well understood. Therefore, there are many additional cellular signaling 
factors remaining to be identified for this complicated uptake mechanism and thus, for 
vaccinia entry.  
To take an unbiased systematic approach toward the identification of these 
cellular factors, we developed a system using the model organism Drosophila to perform 
a high-throughput RNA interference (RNAi) screen for cellular kinases and 
phosphatases required for early steps in vaccinia infection. The Drosophila system is 
particularly amenable to this approach for a number of reasons including: reduced 
redundancy in the genome, high conservation with mammalian systems, efficient RNAi, 
and previous success with this system to identify cellular factors required for viral 
infection [8,295]. This Drosophila system is permissive to early steps in the vaccinia 
infection cycle allowing us to specifically dissect the role of cellular factors involved in the 
infectious entry process. 
Using this system, we identified seven genes that contribute to vaccinia infection, 
including the three subunits of the AMP-activated kinase (AMPK) complex, the master 
energy sensor of the cell. Importantly, the requirement for AMPK in vaccinia infection is 
conserved in mammalian cells, and is specifically required for vaccinia-induced 
macropinocytic entry. Further characterization led to the discovery that AMPK controls a 
variety of virus-independent actin-dependent processes including lamellipodia formation 
and cell migration. Altogether, we found a new role for AMPK in actin dynamics. 
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2. Results 
a. Vaccinia Infection in Drosophila Cells 
Since vaccinia infection of Drosophila cells has not been reported, we first 
characterized the course of infection in Drosophila cells. Using a reporter virus 
expressing Beta-galactosidase (B-gal) under the control of an early/late promoter which 
is active during all stages of vaccinia infection, we found that vaccinia infection is dose-
dependent with maximal expression at 48 hours post infection (hpi) (Supplementary 
Figure 1). Next, we infected Drosophila cells using reporter viruses that express B-gal 
under the control of temporally regulated vaccinia promoters that are active during 
different phases of the virus replication cycle. We found that Drosophila cells were 
efficiently infected as measured by the production of B-gal from an early/late promoter (p 
7.5) or by the production of E3L protein, a vaccinia gene product expressed early in 
infection while, there was very little expression of B-gal from either an intermediate 
promoter (G8R), or a late promoter (p11) (Figure 3.1A). Consistent with these findings, 
we have been unable to detect vaccinia DNA replication (data not shown) suggesting a 
block to infection following early protein synthesis. These findings demonstrate that while 
vaccinia is unable to complete all stages of the lifecycle in Drosophila cells, entry and 
early expression occur, providing a model system to study the host factor requirements 
of vaccinia entry. 
Previous studies have shown that efficient vaccinia entry is dependent upon the 
endocytic route of macropinocytosis [83]. In order to assess whether host requirements 
for vaccinia entry were conserved between Drosophila and mammalian cell lines, we 
tested whether inhibition of macropinocytosis attenuated infection in these disparate cell 
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types. To this end, we treated cells with several known inhibitors of macropinocytosis 
and vaccinia entry including; an actin inhibitor Latrunculin A, PI3K inhibitor Wortmannin, 
Na/H antiporter inhibitor EIPA, and PKC inhibitor Rottlerin [78,83]. We found that each of 
these drugs significantly inhibited vaccinia infection in both human and Drosophila cells 
(Figure 3.1B-C, quantified in Supplementary Figure 2). These data show that at least 
early steps in the viral lifecycle are dependent upon similar pathways in insect cells 
allowing us to use this model to identify additional factors required for vaccinia infection 
in mammalian cells. 
b. RNAi Screen of Drosophila Kinome 
  In order to systematically probe the requirements for cellular signaling factors in 
early vaccinia infection, we developed a quantitative assay amenable to RNAi using 
virally encoded B-gal expression as a measure of early infection. While a non-targeting 
negative control dsRNA (GFP) had no effect on the percentage of infected cells, knock-
down of B-gal by RNAi reduced the percentage of B-gal expressing cells 17-fold, 
indicating that vaccinia infection can be quantitatively assayed using this system (Figure 
3.2A). Moreover, dsRNA targeting the cellular gene Rab5, a small GTPase required for 
many endocytic processes including macropinocytosis [89] also significantly decreased 
vaccinia infection, validating that we can identify cell-encoded factors required for 
vaccinia infection using this approach (Figure 3.2A and 3.2D).  
We used this assay to perform an RNAi screen against the Drosophila kinome to 
identify novel signaling factors that promote vaccinia infection (Schematic diagram 
Figure 3.2B). This screen consisted of approximately 440 unique genes (~200 kinases, 
~90 phosphatases, and ~150 regulator factors) arrayed onto 384 well plates. 
46 
 
Additionally, negative control wells were included containing either no dsRNA (15 wells) 
or dsRNA targeting GFP (28 wells), which is not expressed in this system. Lastly, 21 
positive control wells with dsRNA targeting lacZ were included (Figure 3.2B light blue). 
Drosophila cells were seeded in these pre-arrayed 384 well plates, incubated for three 
days to allow knock down of each targeted gene, and then infected with vaccinia virus 
for 48 hours. For the screen, a baseline infection of 10% was within the linear range and 
was achieved at an MOI of 1.25 (Supplementary Figure 1C). The plates were fixed and 
processed for immunofluorescence using B-gal expression as a measure of infection, 
and counter-stained to monitor cell number. Automated microscopy and image analysis 
were used to quantify the percent infection (B-gal+/Total Nuclei) that was transformed 
into Robust Z scores for each plate, and the Robust Z scores of the 2 replicates were 
plotted against each other (Figure 3.2B). Positive candidates were defined as having a 
Robust Z score of < -2 in duplicate screens (p<0.05). Using these metrics, we identified 
8 genes (2%, orange and pink Figure 3.2B). In addition to these 8 factors, we identified 
20 out of 21 (95%) of the positive control lacZ dsRNAs (Figure 3.2B light blue) and none 
of the 43 negative controls (non-targeting dsRNA and empty wells). We also monitored 
the toxicity of the dsRNA treatments and found that none of the 8 genes that inhibited 
infection were cytotoxic (<25% decrease in cell number, Table1). In contrast, we found 
that while 17 wells reduced cell number by >25% in duplicate screens, none of these 
genes also inhibited infection. Therefore, our screen revealed host factors required for 
robust infection that are not required for cell viability. Notably all 8 genes have human 
homologs (Table 1), including all 3 subunits of the AMP-activated kinase (AMPK) 
complex (SNF1A (AMPKα), SNF4Agamma (AMPKγ) and alicorn (AMPKβ)) (Figure 3.2B 
pink), a heterotrimeric complex involved in maintaining cellular energy homeostasis. 
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RNAi resulted in ~3-fold reduction in vaccinia infection when AMPK was depleted 
(Figure 3.2C). 
Non-overlapping secondary dsRNAs were generated for each of the 8 genes and 
were tested to confirm the role of each of these genes in vaccinia infection. Seven of the 
genes validated (88%). Importantly, among the genes that validated were those 
encoding the three subunits of the AMPK complex (Figure 3.2D, Supplementary Figure 3 
and Table 1). Moreover, RT-PCR confirmed that AMPKα was depleted by dsRNA 
treatment against AMPKα (Supplementary Figure 4A). Furthermore, we found that loss 
of AMPKα or AMPKγ also led to a defect in early viral mRNA accumulation compared to 
control (Figure 3.2E), suggesting that AMPK is required upstream of viral mRNA 
production in Drosophila, perhaps at the stage of entry. 
c. AMPK Promotes Vaccinia Infection in Mammalian Cells 
AMPK is an important sensor of intracellular energy that is conserved in 
eukaryotes ranging from yeast to humans [174]. While Drosophila encodes only one 
copy of each AMPK subunit, mammals have multiple isoforms of each subunit encoded 
by several distinct genes (α1, α2, β1, β2, γ1, γ2, γ3) which can produce at least 12 
possible heterotrimeric combinations [176]. The lack of redundancy in Drosophila 
allowed our identification of AMPK by single gene RNAi. We used this Drosophila 
system as a tool to identify novel host factors that contribute to vaccinia infection, but 
since Drosophila is not a natural host, we were interested in determining the role of 
AMPK in a more biologically relevant context.  
To investigate the role of AMPK in vaccinia virus infection of mammalian cells, 
we took advantage of mouse embryonic fibroblasts (MEFs) that are genetically altered 
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and null for both AMPKα subunits, AMPKα1 and AMPKα2 (AMPKα1/AMPKα2 -/-) and 
verified the lack of these proteins by immunoblot analyses (Supplementary Figure 5) 
[177,178,296]. These cell lines divide and grow indistinguishably from their sibling 
control AMPKα1/AMPKα2 +/+ cells (wild type) (data not shown). We challenged either the 
AMPKα1/AMPKα2-/- cells or their sibling control wild type cells with vaccinia virus and 
measured infection using a plaque assay. This revealed a 20-fold decrease in plaque 
number and a 15-fold decrease in plaque area in AMPKα1/AMPKα2 -/- compared to wild 
type cells (Figure 3.3A-C). The requirement for AMPK was also observed for the closely 
related poxvirus, cowpox virus (Figure 3.3D, quantified in Supplementary Figure 6). 
These decreases in infectivity were specific for poxviruses and not simply due to a 
decrease in overall cell health since several unrelated RNA viruses, including Vesicular 
Stomatitis virus (VSV) grew as well in the AMPK deficient MEFs compared to wild type 
(Supplementary Figure 7 and data not shown). This suggests that AMPK deficient cells 
are capable of supporting all stages of virus infection; including at least some forms of 
endocytosis and endosomal trafficking since VSV enters cells through clatherin-
mediated endocytosis [297]. Therefore, we identified a specific requirement for AMPK in 
poxvirus infection but not for viral infection generally. In addition to plaque assays we 
also monitored vaccinia infection by immunofluorescence, immunoblot, and Northern 
blot and found that there was a significant decrease in vaccinia virus replication in 
AMPKα1/AMPKα2 -/- cells in each assay (Supplementary Figure 8A-C). This suggests 
that AMPK promotes early steps of the vaccinia lifecycle in mammalian cells as well as 
Drosophila. Finally, to verify that the requirement for AMPK was not MEF-specific we 
tested whether inhibition of AMPK in the human osteosarcoma cell line U2OS 
attenutated vaccinia infection using two approaches. First, we pre-treated U2OS cells 
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with the AMPK inhibitor Compound C or vehicle and challenged these cells with vaccinia 
[258]. Again, we found that inhibition of AMPK attenuated infection (Figure 3.4A, B). 
Next, we depleted AMPKα1, AMPKα2, or both AMPKα1 and AMPKα2 using siRNAs and 
observed a decrease in vaccinia infection (Supplementary Figure 9A, B). We confirmed 
knock-down by immunoblot (Supplementary Figure 9C). Together, these data show that 
vaccinia infection is dependent upon AMPK for infection across disparate cell types 
including Drosophila, human and mouse. 
d. Vaccinia Infection Activates AMPK 
AMPK is activated through phosphorylation of a threonine residue on the 
catalytic α subunit, which can be triggered by a variety of stimuli including an increase in 
the cellular ratio of AMP/ATP [173,184,298,299,300,301]. Since AMPK promotes 
vaccinia infection, we tested whether vaccinia infection activates AMPK. We used a 
phospho-specific antibody against AMPKα to measure AMPK activation and observed 
an increase in phospho-AMPKα within 10 minutes of vaccinia infection. Likewise, 
treatment with 2-deoxyglucose (2DG), a known activator of AMPK, led to an increase in 
AMPK phosphorylation, while little phosphorylation was detected in untreated controls 
(Figure 3.4C). This increase was not due to changes in total AMPK levels, and suggests 
that AMPK becomes activated very early in vaccinia infection. 
e. Known Upstream Activators of AMPK Are Not Required for Vaccinia Infection  
 Several upstream kinases have been implicated in AMPK activation under 
different conditions. The classic activator of AMPK is the tumor suppressor LKB1, which 
activates AMPK in response to energy deprivation [185,186]. In Drosophila, LKB1 is the 
only described upstream kinase required for AMPK activation and lkb1 mutants 
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phenocopy ampk mutants [175,242]. In contrast, in mammalian systems, LKB1 is the 
upstream kinase in response to energy deprivation, while additional upstream kinases, 
such as CaMKKβ have been implicated in AMPK activation under other conditions 
[187,188]. We tested whether LKB1 was required for vaccinia infection using cells that 
are null for LKB1 [302] and complemented with either vector alone (LKB1-/-; Vec), or an 
LKB1 cDNA (LKB1-/-;LKB1) (Supplementary Figure 10) and found that loss of LKB1 had 
no effect on vaccinia infection in mammalian cells (Figure 3.4D). Likewise, using RNAi to 
deplete LKB1 in Drosophila cells, we found that it was dispensable for infection by 
immunofluorescence (Figure 3.4E) and Northern blot (Figure 3.4F). RT-PCR analysis 
validated that LKB1 was indeed knocked down in Drosophila cells (Supplementary 
Figure 4B). We also tested whether CaMKK, the other well-established AMPK activator 
in mammalian systems, was required for vaccinia infection. To this end, we pre-treated 
U2OS cells with the CaMKK inhibitor STO609 prior to infection, and found no effect on 
vaccinia infection with doses up to 5 ug/ml (Figure 3.4A, B). Taken together, these data 
show that vaccinia infection is AMPK-dependent but LKB1 and CaMKK-independent. 
f. AMPK Promotes Vaccinia Entry 
Given that loss of AMPK led to a decrease in both viral mRNA and protein 
production (Figure 3.2, Supplementary Figure 8), we tested whether AMPK was required 
for efficient virus entry. We monitored viral entry into wild type or AMPKα1/AMPKα2 -/- 
MEFs using a fluorescence-based assay. We prebound virus to the cells, and then 
allowed infection to proceed for one hour. Incoming virus particles were visualized using 
an antibody against L1R, a membrane-bound viral surface protein (Figure 3.5A). 
Deconvolution of was used to visualize vaccinia inside of cells (Figure 3.5A, XZ view). 
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Quantification revealed a ~3-fold reduction in the number of AMPK mutant cells that 
internalized virus (Figure 3.5B). These data show that AMPK promotes infection at the 
stage of entry, although we have not ruled out that virus binding could also be affected 
by lack of AMPK. 
We were also interested in whether AMPK played a role in vaccinia infection 
downstream of entry. First, we monitored both early and late gene expression and found 
that while the percentage of cells expressing an early protein (E3L) or a late protein 
(L1R) was reduced in AMPKα1/AMPKα2 -/- MEFs compared to wild type, 100% of the 
cells that expressed early genes also expressed late genes, indicating no further block to 
replication (Supplementary Figure 11A). We also measured the infectivity of virus 
produced from AMPKα1/AMPKα2 -/- MEFs. We found a ~3-fold decrease in virus titer 
produced from AMPKα1/AMPKα2 -/- MEFs compared to wild type (Supplementary Figure 
11B) which is similar to the decrease in viral entry (Figure 3.5B). These data suggest 
that while fewer AMPK deficient cells produce virus, the vaccinia released from these 
cells is as infectious as virus produced from wild type cells. Therefore, while AMPK is 
important for entry, it is dispensable for later steps in the viral lifecycle. 
g. AMPK Is Required for Vaccinia Induced Macropinocytosis 
Previous studies established that a major entry route for vaccinia is 
macropinocytosis, which is required for and induced by vaccinia infection [83]. Since we 
observed a defect in viral entry in the AMPK mutant cells (Figure 3.5), and that inhibitors 
of macropinocytosis attenuated vaccinia infection (Figure 3.1), we tested whether AMPK 
plays a role in vaccinia-induced macropinocytosis. Macropinocytosis can be directly 
monitored by fluorescently labeled dextran uptake [303]. Neither wild type nor 
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AMPKα1/AMPKα2 -/- MEFs efficiently endocytosed dextran under resting conditions 
(Figure 3.6A). However, upon vaccinia infection, macropinocytosis was dramatically 
induced in wild type MEFs as measured by an increase in dextran uptake into the cell. In 
contrast to the large number of dextran punctae observed in the infected wild type 
MEFs, AMPKα1/AMPKα2 -/- MEFs did not efficiently take up the dextran in the presence 
of virus (Figure 3.6A). We quantified the level of vaccinia-induced macropinocytosis in 
the wild type versus AMPK deficient cells and found an approximately five-fold reduction 
in the percentage of cells undergoing macropinocytosis (Figure 3.6B).   
Furthermore, we found a decrease in vaccinia-induced dextran uptake in human 
U2OS cells pretreated with Compound C compared to vehicle control (Figure 3.6C). 
Quantification revealed an approximately five-fold decrease in the percentage of U2OS 
cells undergoing vaccinia-induced macropinocytosis when AMPK is inhibited (Figure 
3.6D). Together, these data show that virus-induced macropinocytosis is dependent 
upon AMPK in disparate cell types and hosts. 
In contrast to this dependence of macropinocytosis on AMPK, there was no 
defect in transferrin uptake in AMPKα1/AMPKα2 -/- MEFs (Supplementary Figure 12), 
indicating that receptor-mediated endocytosis is not controlled by AMPK. This is 
consistent with our observation that VSV infection is not attenuated in AMPKα1/AMPKα2 
-/- MEFs as VSV enters cells by receptor-mediated endocytosis and not 
macropinocytosis (Supplementary Figure 7). 
h. AMPK Promotes Lamellipodia Formation 
 One of the early steps in macropinocytosis involves extensive actin remodeling 
characterized by membrane ruffling and lamellipodia formation. We were interested in 
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determining whether AMPK was required for this early step in the macropinocytic 
pathway, and whether the requirement for AMPK in macropinocytosis was vaccinia-
dependent or if AMPK was required more generally for actin remodeling. Therefore, to 
test whether AMPK controlled actin-dependent remodeling independent of viral infection, 
we treated cells with phorbol myristic acid (PMA), which induces cells to undergo high 
levels of actin-mediated ruffling and lamellipodia formation; this is dependent on Rac1, a 
small Rho family GTPase that is also required for macropinocytosis and vaccinia 
infection [78,304,305,306]. Dramatic lamellipodia formation, seen as thick bands of actin 
at the cell periphery, were observed in wild type MEFs stimulated with PMA, but 
abrogated in AMPK-deficient cells (Figure 3.7A, arrows). We also monitored PMA-
induced ruffling using live cell imaging and observed a significant defect in the AMPK 
mutant MEFs. 
In addition, we monitored the localization of Rac1 during PMA-induced 
lamellipodia formation in the wild type and AMPK deficient cells and found that both 
Rac1 re-localization and actin mobilization are defective in AMPK deficient cells (Figure 
3.7B, arrows) suggesting that the defect is upstream of or parallel to Rac1 activation. 
 While our studies identified AMPK as a critical kinase required for vaccinia 
infection and actin dynamics, we found that LKB1 was dispensable for infection. This led 
us to test whether actin-dependent lamellipodia formation and ruffling was also LKB1-
independent. We found that there was no defect in PMA-induced lamellipodia and 
ruffling in LKB1-deficient cells (Figure 3.7C, arrows). This was not unexpected since 
HeLa cells, a cell type routinely used for studies on actin dynamics, are mutant for LKB1, 
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and can still undergo lamellipodia formation, and macropinocytosis [83,307,308,309]. 
Therefore, we found that the actin remodeling activity of AMPK is independent of LKB1. 
i. AMPK Promotes Cellular Motility 
Since extensive actin remodeling and Rac1 membrane localization are required 
for lamellipodia formation, macropinocytosis, and vaccinia infection [78,304,305,306], we 
tested whether AMPK was required for another Rac1-dependent actin-dependent 
process namely in vitro wound healing [310]. For these studies, we created wounds in a 
confluent monolayer of either wild type or AMPKα1/AMPKα2-/- MEFs by scratching the 
surface, and monitored wound closure over time. Using this assay we found that there 
was a significant delay in the migration of AMPK-deficient MEFs into the wound 
compared to wild type cells (Figure 3.7D, E). While the wound was completely healed 24 
hours after wounding in wild type cells, a sizable gap in the monolayer was still present 
in AMPK deficient cells, indicating a delay in wound healing and reduced motility. During 
this motile state, cells undergo a dramatic change in shape, with lamellipodia forming at 
the leading edge directing cell migration to close the wound. We observed the formation 
of lamellipodia in the WT MEFs at the edge of the wound while AMPK mutant MEFs did 
not polarize (Supplementary Figure 12). Consistent with our observations that the role 
for AMPK in actin dynamics is LKB1-independent, we found that wound healing is 
unaffected by the loss of LKB1 (Supplementary Figure 14). 
3. Discussion 
Cell penetration is a critically important step in viral infection, and one that is 
generally driven by cellular factors and signaling pathways. First, viruses must attach to 
the cell surface and bind to the viral entry receptor, which often initiates signaling within 
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the cell. Next, viruses must fuse or penetrate the cellular membrane either at the cell 
surface, or in many cases, within intracellular compartments by taking advantage of the 
endogenous endocytic machinery. Since there is an array of different endocytic 
mechanisms, there is great diversity in the strategies used by viruses for entry. 
Therefore, studying virus entry has increased our understanding not only of viral 
infection, but also of the normal cellular processes of endocytosis [88].  
To further dissect the cellular signaling requirements of vaccinia infectious entry, 
we developed an unbiased loss-of-function screening platform in Drosophila cells, and 
identified seven cellular factors required for vaccinia infection. Amongst the genes were 
all three subunits of AMPK, implicating the entire complex in vaccinia infection. Further 
studies showed that in addition to its role in Drosophila, AMPK is also required in murine 
and human cells for poxvirus infection at the stage of entry. 
Studies indicate that vaccinia virus can enter cells through multiple routes via as 
of yet unidentified receptor(s). Studies suggest that virus particles can fuse either at the 
plasma membrane or from within endosomal compartments, dependent on cell type and 
virus strain [59,80,81,85,86]. Importantly, a major endocytic pathway for vaccinia entry 
has recently been described as macropinocytosis [77,83]. Our data as well as previous 
reports support the idea that vaccinia uses macropinocytosis for entry, but not 
exclusively. We and others have shown partial inhibition of vaccinia infection using a 
variety of drugs that are well-established inhibitors of macropinocytosis [78,83]. 
However, in no case was vaccinia entry completely dependent upon macropinocytosis 
for infection, demonstrating that the virus can use alternative routes for entry. 
Nevertheless, macropinocytosis is required for efficient entry across broad cell types 
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suggesting that inhibition of this pathway may attenuate infection sufficiently to allow for 
immune-mediated clearance of the infection.  
The process of macropinocytosis drives non-specific uptake of extracellular fluid, 
large portions of the plasma membrane, as well as large particles. Macropinosomes, 
unlike coated vesicles, are morphologically heterogenous, and can vary greatly in size 
from 0.2-10μm in diameter, sufficient to accommodate the large size of vaccinia virus 
particles (~0.3μm) [47,87]. Classic induction of macropinocytosis by growth factor 
receptor signaling stimulates ruffles, or sheet-like extensions of the plasma membrane, 
formed by assembly of actin filaments beneath the plasma membrane that form cups 
that contract and close to form macropinosomes [87]. This process is driven by signaling 
events initiated at the plasma membrane and are thought to involve a number of kinase 
families including PI3K, PI5K, PKC, serine/threonine kinases, and receptor tyrosine 
kinases. In addition, as many different inducers of macropinocytosis have been 
identified, there are likely multiple pathways that converge on the activation of 
macropinocytosis, adding to the complexity of this cell biological pathway [87]. While 
several specific kinases, such as Pak1, and LIM kinase have well described roles in 
macropinocytosis [311,312], there is much that remains unclear. Here, we have found a 
role for an additional kinase, AMPK, in promoting vaccinia entry through its role in 
macropinocytosis. We have found that AMPK deficiency attenuates vaccinia infection, 
concomitant with reduced entry and fluid-phase uptake, supporting an important role for 
AMPK in vaccinia-induced macropinocytic entry.  
The process of macropinocytosis involves several steps including extensive 
actin-mediated membrane ruffling, cup formation, and finally cup closure, which requires 
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the fusion of plasma membranes to close off the macropinosome, followed by fission to 
separate the macropinosome from the plasma membrane [87]. We discovered that 
AMPK is required for the formation of lamellipodia and affects the recruitment of Rac1 to 
the cell periphery, suggesting that the role of AMPK in macropinocytosis lies in the initial 
rearrangement and reorganization of the actin cytoskeleton.    
While we have shown that AMPK contributes to actin remodeling during vaccinia-
induced macropinocytosis, we also found that AMPK plays a role in other virus-
independent remodeling processes including cell migration. During this process, forward 
movement is driven by the extension of a leading edge protrusion or lamellipodium, 
followed by contraction at the rear. This protrusive force is generated by localized 
polymerization of actin mediated by Rac1 [313]. In addition to its role in controlling 
ruffling upstream of macropinocytosis, we found AMPK also has an essential role in 
cellular motility and wound healing, demonstrating a broad role in Rac1-dependent actin 
modulation. Previously, Rac1 has been implicated in nitric oxide production and glucose 
uptake downstream of AMPK [314,315]. This role for AMPK and Rac1 in glucose uptake 
via the translocation of the major glucose transporter GLUT-4 is quite interesting 
because this may provide a direct link between AMPK’s role in energy homeostasis and 
the cytoskeleton [316,317,318].  
While the best understood role of AMPK is its role in metabolism, recent 
evidence suggests this kinase also has a crucial role in regulating cell structure and 
polarity through engagement with the actin cytoskeleton. In Drosophila, loss of AMPK 
leads to defects in mitotic division and epithelial cell polarity accompanied by disruption 
of the actin cytoskeleton [175]. In some mammalian epithelial cell lines, AMPK activation 
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leads to polarization characterized by the formation of an actin brush-border or tight 
junction assembly [175,236,237]. Additionally, AMPK activation can induce astrocyte 
stellation, and actin stress fiber disassembly [239]. Finally, studies using Compound C 
and AMPK activators linked AMPK to macropinocytic uptake of albumin in murine 
macrophages [240]. Taken together with our new data, this accumulating evidence 
suggests a broad and conserved role for AMPK in a variety of cellular processes that 
require actin cytoskeletal rearrangements.  
The precise signaling events that lead to these AMPK-dependent cytoskeletal 
changes remain unclear. Several upstream kinases have been shown to activate AMPK 
under different stimuli. The best studied of these is the tumor suppressor LKB1 which 
activates AMPK in response to changes in cellular energy levels [185,186]. Additionally, 
AMPK can be activated in response to changes in intracellular calcium levels by 
CaMKKβ, and further evidence suggests that TGFβ-activating kinase (TAK1) may serve 
as a third upstream activator [187,188,190]. Previous studies demonstrated that LKB1 is 
an important mediator of cell polarity at least in part through signaling to AMPK, and has 
been shown to drive actin brush border formation, and the translocation of apical and 
basal markers during the establishment of polarity [175,236,237,242,243].  We found 
that at least some AMPK-dependent cytoskeletal changes are independent of LKB1 and 
CaMKK including lamellipodia formation, macropinocytosis and wound healing. These 
different actin-dependent outcomes could be controlled by the unique downstream Rho 
GTPase family members that may become activated by AMPK depending on the 
stimulus and upstream kinase (such as Rac1, which is associated with lamellipodia 
formation and macropinocytosis) [91,92]. Study of the Rho family GTPases activated by 
AMPK under different stimuli may resolve some of these issues.  
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In addition to the three subunits of AMPK discovered through screening the 
kinome, we identified four other genes that promote vaccinia infection: Pi3K68D, Fab1, 
Stam, and CG9311, all of which have human homologs. Pi3K68D, Fab1, and Stam are 
kinases while CG9311 is the only phosphatase identified in the screen. As kinases are 
druggable targets, and many known factors involved in macropinocytosis are kinases, 
we are particularly interested in the role of these kinases in vaccinia infection. Both 
Pi3K68D (PIK2C2A) and Fab1 (PIP5K3/PIKfyve) have roles in metabolism of 
phosphatidylinositol (PtdIns), an important component of membrane trafficking, 
cytoskeletal rearrangements, and macropinocytosis. In particular, Pi3K68D is a member 
of the class II family of PI3Ks that produce PtdIns(3)P downstream of growth factor 
stimulation, and can modulate the activity of Rho GTPases such as Rac1 and Cdc42. 
Class II PI3Ks have a critical role in lamellipodia formation and in cell migration, 
localizing to the leading edge of migrating cells [319,320]. Interestingly, class I PI3K 
have also been implicated in vaccinia infection, during virus entry, and also later stages 
of infection [83,321,322]. Fab1, the PtdIns(3)P 5-kinase that converts PtdIns(3)P into 
PtdIns(3,5)P2, has been implicated in fluid-phase uptake, transport, and endosomal 
acidification [323,324]. The third kinase, Stam (STAM, STAM2) is activated by cytokine 
and growth factor stimulation, and localizes to early endosomes, where it is involved in 
endosomal sorting [325,326]. Since these kinases have roles either in trafficking to or 
from the plasma membrane, or in cytoskeletal rearrangements, and have been 
implicated in processes related to macropinocytosis, it is quite possible that they also 
play a direct role vaccinia entry. Perhaps Pi3K68D is involved in promoting cytoskeletal 
rearrangements that lead to macropinocytosis, while Fab1 and Stam could be involved 
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sequentially in later entry steps leading to membrane fusion once a macropinosome has 
been internalized.  
Rearrangements in the actin cytoskeleton are crucial not only for vaccinia 
infection, but also for many essential cellular processes including: cell division, 
establishment and maintenance of polarity, cellular motility, and uptake of extracellular 
fluids, each of which must be carefully regulated. While these various processes have 
different outcomes for the cell, they share several important signaling components, with 
AMPK as a central mediator. Further characterization of AMPK as well as these 
additional new factors is required to determine their precise role in vaccinia infection and 
whether they interact with AMPK, macropinocytosis, or other actin-dependent 
processes. How AMPK activation in response to different signals leads to these 
disparate changes in the actin cytoskeleton, and how these processes fit into the larger 
network of AMPK-dependent pathways will drive future studies. Lastly, the development 
of more selective AMPK inhibitors or other inhibitors of macropinocytosis may be useful 
against poxviruses, and other viruses that hijack this endocytic route for their entry 
mechanism. 
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Figure 3.1: Vaccinia virus undergoes infectious entry in Drosophila cells.  A. 
Drosophila cells were infected with three different recombinant vaccinia viruses 
expressing B-gal driven by an early/late (p7.5), intermediate (G8R), or late (p11) 
vaccinia promoter. Each virus expresses E3L protein from an endogenous early 
promoter. After 48 hours, infection levels were assessed using B-gal or E3L-specific 
antibodies. B-C. Vaccinia infection is dependent upon known mediators of 
macropinocytosis. B. Human U2OS cells were pretreated with: Latrunculin A, 
Wortmannin, and Rottlerin at 5μM; EIPA at 12.5μM for 1 hour and challenged with 
vaccinia (MOI=10) for 8 hours. C. Drosophila DL1 cells were treated with: Latrunculin A, 
Wortmannin, and Rottlerin at 5μM; EIPA at 50μM for 1 hour and challenged with 
vaccinia (MOI=20) for 24 hours. Cells were fixed and processed for immunofluorescence 
using E3L expression (green) as a marker for infection, and Hoescht 33342 (blue) to 
visualize nuclei. Percent infection is the average of four images in a representative of 
three experiments. 
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Figure 3.2: High-content RNAi screen identifies cellular factors required for 
vaccinia infection.   A. Cells were pre-treated with the indicated dsRNAs and infected 
with E/L (p7.5) B-gal vaccinia at multiplicity of infection (MOI) of 1.25 for 48 hours. 
Percentage of infected cells is calculated from ((B-gal+, green)/ (nuclei, blue)). B. 
Schematic of high-throughput RNAi screening. Cells were plated in 384 well plates 
arrayed with gene-specific dsRNA targeted against the Drosophila kinome. After three 
days, the cells were infected with E/L B-gal vaccinia at MOI=1.25 for two days and then 
processed for immunofluorescence. Automated image analysis was used to determine 
the percentage of infected cells and used to identify the positive candidates (Z<-2 in 
duplicate). Candidates in light blue represent the B-gal-depleted positive controls, and 
those in pink represent the three subunits of the heterotrimeric AMPK complex. Other 
candidates are indicated in orange. C. Examples of primary screen data including AMPK 
components that when depleted resulted in a significant decrease in the percentage of 
B-gal-positive cells. D. Independent dsRNAs against each of the three AMPK subunits: 
AMPKα (SNF1A), AMPKβ (alicorn) and AMPKγ (SNF4Agamma). RNAi was performed 
and cells were infected at an MOI=5. Percent infection was measured and the mean+SD 
is shown; * indicates p<0.05 compared to control in three independent experiments. E. 
Northern blot analysis was performed on RNA extracted from cell lysates pretreated with 
dsRNA targeting the indicated genes and probed for B-gal, and a loading control RpS6. 
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 Table 3.1: Candidate genes identified and validated. 
 
 
 
 
 
 
 
 
 
% infection 
Robust Z score Nuclei fold change 
validated?% infection f rom median 
Drosophila
Gene 
Human 
Gene Screen #1 Screen #2 Screen #1 Screen #2 Screen #1 Screen #2 
median 3.9 7 1 1
B-gal 0.9 1.2 -17.5 -10.8 1 1
SNF1A 
(AMPKα) PRKAA2 1.7 2.8 -4.5 -5.4 0.8 1 Yes
SNF4Agamma 
(AMPKγ) PRKAG2 1.1 1.9 -3.9 -7 1 0.9 Yes
Alicorn
(AMPKβ) PRKAB1 0.3 4.2 -3.9 -3.4 1 1.1 Yes
Fab1 PIKfyve 3.4 4.5 -2.3 -2.2 1 1 Yes
Pi3K68D  PIK3C2A 2.4 3.3 -3.8 -3.9 1.1 1.1 Yes
Stam STAM 3.3 4.5 -2.1 -2.5 1 1.1 Yes
CG9311 PTPN23 3.1 2.5 -3.8 -5.7 1 0.9 Yes
Strn-Mlck MYLK 0.6 4.8 -2.5 -2.8 1 1.1 No
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Figure 3.3: AMPKα promotes poxvirus infection in mammalian cells.  A. Vaccinia 
virus plaque assays were performed with wild type or AMPKα1/AMPKα2 -/- MEFs. 
Representative data from the10-5 dilution of virus is shown. B. Quantification of plaques 
from A. presented as the normalized mean+SD of wild type plaques from four 
experiments;* indicates p<0.05. C. The diameter of 30 representative plaques in each 
duplicate well from A. was used to calculate the average plaque area, which is displayed 
as the normalized mean+SD in triplicate experiments; * indicates p<0.05. D. Cowpox 
virus plaque assays were performed with wild type or AMPKα1/AMPKα2 -/- MEFs. 
Representative data from the10-5 dilution of virus is shown. 
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Figure 3.4: Vaccinia infection induces AMPK activation, but is independent of 
LKB1 and CaMKK. A.  Human U2OS cells were pre-treated with vehicle, Compound C 
(1-5 μM), or STO609 (1-5μg/mL) and then infected with vaccinia (MOI=10) for 8 hours 
(E3L, green; nuclei, blue). A representative of 3 experiments is shown. B. Percent 
infection of A. was measured and the mean+SD is shown; * indicates p<0.05 compared 
to control in three independent experiments. C. Cells were pretreated with vaccinia virus 
(MOI=20) at 16°C for 1 hour, and then infected at 37°C or treated with 2DG, a known 
inducer of AMPK phosphorylation. Lysates were collected at the indicated time points 
post treatment and assayed by immunoblot for phospho-AMPK. A representative of 3 
experiments is shown. D. LKB1 -/- MEFs were complemented with a vector control 
(LKB1-/-,Vec) or FLAG-LKB1 cDNA (LKB1-/-, LKB1) and subsequently infected with 
vaccinia at the indicated MOI for 8 hours, and processed for immunofluorescence. 
Percent infection was quantified using automated image analysis. A representative of 
two experiments is shown. E. RNAi against LKB1 in Drosophila cells had no effect on 
infectivity compared to RNAi against negative control luciferase as measured by 
immunofluorescence. F. LKB1 knock down in Drosophila has no effect on vaccinia early 
mRNA levels as measured by Northern blot. Cells were pretreated with dsRNAs against 
negative control luciferace, positive controls E3L (viral) and Rab5 (cellular), as well as 
AMPKα and LKB1 and probed as indicated. 
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Figure 3.5: AMPK promotes vaccinia entry. A. Wild type or AMPKα1/AMPKα2 -/- 
MEFs were either infected or mock-infected with vaccinia, and the L1R membrane 
protein (red) was monitored to visualize incoming virus. Nuclei (blue) and actin (green) 
were also stained. Images are presented as max projection along with XZ insets. 
Representative images of triplicate experiments are shown. B.  The percentage of cells 
undergoing vaccinia entry was quantified (n>30 for each condition).  
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Figure 3.6: AMPK is required for vaccinia-induced macropinocytosis. Fluid phase 
dextran uptake assays were performed in the presence or absence of virus. A. Wild type 
and AMPKα1/AMPKα2 -/- MEFs were either infected or mock-infected and treated with 
FITC-dextran (red), processed for microscopy, and stained to visualize actin (phalloidin 
(green)) and nuclei (Hoescht 33342 (blue)). Representative images from triplicate 
experiments are shown. B. The percentage of MEFs with dextran punctae was 
quantified from three independent experiments with the mean +/- SD shown; * p<0.05.  
C. U2OS cells were treated or mock-treated with the AMPK inhibitor Compound C (10 
μM) 1 hour prior to addition of vaccinia. Texas Red-dextran (red) was added and 
processed as above. D. The percentage of U2OS cells with dextran punctae was 
quantified from three independent experiments with the mean +/- SD shown; *p<0.05. 
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Figure 3.7: AMPK is required for actin-dependent membrane ruffling and wound 
healing independent of LKB1.  A. Cells were treated with vehicle or PMA and stained 
with phalloidin (actin, green) and Hoescht 33342 (nuclei, blue). Arrows indicate 
lamellipodia. Representative images from triplicate experiments are shown. B. Cells 
were treated with PMA and stained with phalloidin (actin, green), anti-Rac1 (red) and 
Hoescht 33342 (nuclei, blue). Arrows indicate colocalization of actin and Rac1 in 
lamellipodia. Representative images from triplicate experiments are shown. C. MEFs null 
for LKB1 (LKB-/-;Vec) or rescued (LKB1-/-,LKB1) were treated with PMA or vehicle and 
stained as A.. Arrows indicate lamellipodia. Representative images from triplicate 
experiments are shown. D.  A scratch was made in a confluent monolayer of wild type or 
AMPKα1/AMPKα2 -/- MEFs, and monitored over time for closure. Representative images 
from triplicate experiments are shown immediately after wounding (T=0) and after 20 
hours (T=20).  E. Reduction in wound width is quantified over time. Data are normalized 
to initial would width at T=0, and presented as means of three independent experiments 
with four wounds per set; * indicates p<0.05 in each experiment. Moreover, the rate of 
wound healing is reduced in AMPK mutants by ANOVA (p<0.001).   
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IV. AMP-ACTIVATED KINASE RESTRICTS RIFT VALLEY FEVER VIRUS INFECTION 
BY INHIBITING FATTY ACID SYNTHESIS 
1. Introduction 
Arboviral pathogens infecting both humans and domestic animals have lead to 
significant world-wide morbidity and mortality and are both a medical and agricultural 
concern. Bunyaviruses are an important group of insect-borne RNA viruses that include 
several disease causing members such as Sin Nombre, Hantavirus, Crimean-Congo 
Hemorrhagic Fever Virus, and Rift Valley Fever virus (RVFV).  RVFV is a mosquito 
borne Category A agent initially endemic to sub-Saharan Africa. However, outbreaks of 
RVFV have recently occurred in Egypt and the Arabian Peninsula, indicating the 
potential of this virus to spread to new geographical areas [98].  
RVFV has particular importance as an agricultural pathogen, where infection of 
livestock can lead to significant morbidity and mortality, particularly among young 
animals, and cause catastrophic abortion rates [98]. Most humans infected with RVFV 
develop self-limited febrile illness, although approximately 1-3% die from the disease 
due to hemorrhagic symptoms [104,106,107,108]. A live-attenuated vaccine MP-12, as 
well as inactivated virus vaccine have been developed for veterinary use [109,110,111]. 
These vaccines can also provide protective immunity in humans; however, they are 
expensive to produce and in the case of MP-12 may not be acceptable in areas where 
RVFV is not endemic [114,115]. Moreover, no effective anti-viral therapies have yet 
been developed against RVFV.  Here we describe a novel mechanism of cellular 
restriction against RVFV mediated through energy-mediated regulation of lipid 
metabolism. 
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Lipid metabolism plays an important role in infection of many viruses that 
replicate in the cytoplasm including RVFV.  An essential feature of these infections is the 
ability of viruses to rearrange and proliferate internal cellular membranes into distinct 
invaginations or vesicle-like structures to compartmentalize the viral replication complex 
and support genome replication [162]. These membranous structures may serve to 
closely coordinate the replication complexes with virion assembly and budding, act as a 
scaffold for the RC to tether viral RNA, increase the local concentration of replication 
components, or prevent detection by the host immune defense system [162]. Depending 
on the virus, these membrane modifications can be derived from distinct cellular 
sources, including ER, golgi, endosomal, and mitochondrial membranes, and may have 
complex biogenesis derived from multiple cellular origins 
[150,163,164,165,166,167,168,169]. Despite these differences there are many 
similarities in the membrane structures induced by different types of viruses suggesting 
commonalities in this induction across multiple virus families [171]. In some cases the 
viral proteins responsible for these changes are known, but host factors are also likely to 
contribute to this process. Importantly these modifications are highly dependent on 
cellular lipid biogenesis pathways and require generation of newly synthesized cellular 
lipids [162].  
 AMP-activated Kinase (AMPK) is a heterotrimeric complex that is an essential 
regulator of lipid metabolism mediated through energy sensing [228]. Under conditions 
of energetic stress, this complex switches the cell from an anabolic to a catabolic state 
by activating oxidative pathways that generate energy while inhibiting synthesis and 
growth pathways in order to return the cell to a state of energy homeostasis [173]. Thus 
AMPK activity is important for survival during periods of stress, and also has implications 
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in type II diabetes, obesity, metabolic syndrome, longevity, and cancer 
[244,245,270,271,272,273,274]. AMPK is a heterotrimeric complex consisting of a 
catalytic alpha subunit, and regulatory beta and gamma subunits [173]. Mammals 
encode multiple isoforms of each subunit encoded by several distinct genes (α1, α2, β1, 
β2, γ1, γ2, γ3) which can produce at least 12 possible heterotrimeric combinations [176]. 
Activation is triggered through binding of AMP or ADP to the Bateman domains of the 
gamma subunit, leading to increased phosphorylation of the threonine 172 on the alpha 
subunit by inhibiting dephosphorylation and inducing allosteric activation 
[180,181,182,183]. The canonical upstream activator of AMPK that catalyzes the 
phosphorylation event is the constitutively active tumor suppressor LKB1, but additional 
activators such as CaMKKβ have also been identified [185,186,187,188,190].  
In particular, AMPK is a potent regulator of lipid metabolism, inhibiting both sterol 
and fatty acid synthesis, while promoting fatty acid oxidation [228]. AMPK 
phosphorylation of acetyl CoA carboxylase (ACC), a rate limiting enzyme in fatty acid 
metabolism, inhibits its activity [229,230]. ACC catalyzes the irreversible conversion of 
acetyl-CoA to malonyl-CoA, a key metabolite that plays multiple roles in fatty acid 
metabolism. First, it is the substrate for fatty acid biogenesis, which drives de novo 
production of palmitate [231]. Second, malonyl-CoA is also a cosubstrate for chain 
lengthening of endogenously synthesized and dietary-derived essential fatty acids into 
higher polyunsaturated fatty acids [232]. Third, malonyl-CoA serves a signaling function 
through inhibition of carnitine palmitoyltransferase I (CPT-1), an essential factor in the 
transport of fatty acids to the mitochondria for beta oxidation [231]. Thus malonyl-CoA 
production by ACC promotes fatty acid synthesis, while inhibiting fatty acid oxidation.  
Mammalian systems encode two nonredundant ACC isoforms, ACC1 and ACC2, which 
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are both inactivated by AMPK-mediated phosphorylation. Some studies suggest that 
malonyl-CoA produced by ACC2 is exclusively involved in fatty acid oxidation, while 
ACC1 contributes to fatty acid biogenesis [228]. Therefore, activation of AMPK through 
stress or low energy conditions induces fatty acid oxidation through ACC2, while 
inhibiting fatty acid synthesis through ACC1.  
We found that AMPK is potently antiviral against RVFV, and this restriction is 
dependent on the upstream activator LKB1. Furthermore, pharmacological activation of 
AMPK inhibited viral infection, and correlated with decreased levels of cellular lipids. 
Mechanistically, we found that AMPK is antiviral through its role in fatty acid metabolism 
as we could bypass the antiviral effects of AMPK by feeding cells palmitate, the 
metabolite produced by ACC. Palmitate treatment restored RVFV infection, suggesting 
that AMPK specifically restricts infection by inhibiting fatty acid synthesis. Since many 
viruses are dependent upon fatty acid biosynthesis for their replication, we tested 
whether AMPK restricted additional RNA viruses. We found that indeed, AMPK has 
antiviral activity against multiple RNA viruses from disparate families. Taken together, 
our data suggest that AMPK activation is broadly anti-viral, and may provide a novel 
anti-viral therapeutic target.        
2. Results 
a. AMPK Expression Restricts RVFV Infection 
 We previously found that AMPK was required for efficient vaccinia infection. This 
finding led us to investigate the role of AMPK in other virus infections; we were 
particularly interested in RVFV as it is a virus that is medically important, but little is 
known about the mechanisms by which it establishes a productive infection. For our 
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studies we used the lab adapted strain MP12 that has only 11 amino acid differences 
from the wild type strain [109]. In order to test the role of AMPK in RVFV infection, we 
took advantage of mouse embryonic fibroblasts (MEF) that are genetically altered and 
null for both of the catalytic α subunits, AMPKα1 and AMPKα2 (AMPKα1/AMPKα2-/-) 
[177,179,296]. We challenged either the AMPKα1/AMPKα2-/- MEFs or their sibling 
control wild type MEFs with MP12 and measured infection by plaque assay (Figure 
4.1A). We found a 6 fold increase in the number of plaques formed in 
AMPKα1/AMPKα2-/- MEFs compared to wild type (Figure 4.1B) concomitant with a four-
fold increase in average plaque area in AMPKα1/AMPKα2-/- MEFs (Figure 4.1C). 
Moreover, RVFV infection was also increased in AMPKα1/AMPKα2-/- MEFs as 
measured by immunofluorescence (Figure 4.1D, quantified in Figure 4.1E), indicating 
that RVFV is able to infect and spread more efficiently in the absence of AMPK. 
 Next we examined if there were differences in infection kinetics in cells lacking 
AMPK by performing a time course in wild type and AMPKα1/AMPKα2-/- MEFs using 
immunofluorescence to measure the percent of infected cells. In both cell types infection 
was first detected at 8 hours post infection (hpi)(Figure 4.1F), indicating similar infection 
kinetics; however, the level of infection was 2-fold higher in AMPKα1/AMPKα2-/- MEFs 
compared to wild type. By 12-16 hpi infection had spread to adjoining cells, as indicated 
by the appearance of foci of infected cells. In wild type MEFs we observed a 2-fold 
increase in infection by 16 hpi compared to 8 hpi, while a 3-fold increase was observed 
in AMPKα1/AMPKα2-/- MEFs during the same time interval (Figure 4.1F), indicating 
enhanced virus spread in the absence of AMPK. 
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 This enhanced spread of the virus to surrounding cells could be due to increased 
production of infectious virus or increased infectivity of virions produced. Next, we 
measured the amount of infectious virus produced in wild type and AMPKα1/AMPKα2-/- 
MEFs over time in a one-step growth curve. Media was collected at various times after 
infection, and released virus was tittered on BHK cells. Little virus was detected at 2-4 
hpi, indicating that input virus was not detected in this assay.  At 12 hpi we observed a 5-
fold increase in infectious virus released from AMPKα1/AMPKα2-/- MEFs compared to 
wild type, indicating enhanced virus production in AMPKα1/AMPKα2-/- MEFs (Figure 
4.1G). Taken together these data suggest that AMPK expression restricts RVFV both 
during initial infection, and through the reduced production of infectious virus.  
b. LKB1 Expression Restricts RVFV Infection 
AMPK is activated through phosphorylation of a threonine residue on the 
catalytic alpha subunit. Several upstream kinases have been implicated in AMPK 
activation under different conditions. The classic activator of AMPK is the tumor 
suppressor LKB1, which phosphorylates AMPK in response to energy deprivation 
[185,186]. This phosphorylation event can be triggered by a variety of stimuli that cause 
a reduction in cellular energy levels, such as glucose starvation or hypoxia [173]. Binding 
of AMP or ADP to the regulatory gamma subunit triggers increased phosphorylation of 
the Thr-172 of the catalytic alpha subunit by the tumor suppressor LKB1 [180,181,182]. 
In order to determine if LKB1 signaling was important for AMPK-mediated RVFV 
restriction, we tested the requirement for LKB1 during RVFV infection. We challenged 
MEFs that are null for LKB1 and complemented with either vector alone (LKB1-/-; Vec), 
or an LKB1 cDNA (LKB1-/-;LKB1) [327] and found increased RVFV infection in MEFs 
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lacking LKB1(Figure 4.2A). Quantification revealed a 2 fold increase in the number of 
plaques (Figure 4.2B) and a 6 fold increase in plaque size (Figure 4.2C) in LKB1-/-; Vec 
MEFs compared to the LKB1 complemented LKB1-/-;LKB1 MEFs. Moreover we 
measured percent infection by immunofluoresence assay for RVFV (Figure 4.2D) and 
found increased percent infection in the LKB1-/-;Vec MEFs compared to those 
complemented with LKB1. Finally, we also measured RVFV production in cells lacking 
LKB1 using a one-step growth curve and found approximately a 4 fold increase in 
infectious virus produced in the LKB1-/-;LKB1 MEFs compared to those complemented 
with LKB1 (Figure 4.2E). Taken together, these data indicate that AMPK signaling 
mediated by LKB1 has antiviral activity against RVFV.  
c. AMPK Activation Restricts RVFV 
 Since LKB1 is the canonical upstream activator of AMPK in response to low 
energy conditions, and AMPK restricts RVFV infection through LKB1, we tested whether 
RVFV was sensitive to drugs that activate AMPK by reducing levels of cellular energy. 
We performed these studies both in MEFs and in the human osteosarcoma cell line 
(U2OS). To this end, we pretreated U2OS cells or MEFs with the glucose analog 2-
deoxyglucose (2DG), or the ATP synthase inhibitor oligomycin for 1 hour prior to 
infecting with RVFV at various MOIs. Both drugs significantly decreased infection of 
RVFV compared to vehicle controls (Figure 4.3A and data not shown). These drugs 
activate AMPK indirectly, and have pleiotropic effects that may also contribute to viral 
infection. Additionally reduction of cellular energy levels may adversely affect viral 
infection independent of AMPK. To control for these possibilities we tested the effects of 
these drugs on vaccinia virus, which is not restricted by AMPK, and instead requires it 
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for efficient entry [327]. Vaccinia was able to enter and infect equally under all treatment 
conditions (Figure 4.3B), indicating that the drug-treated cells are healthy enough to 
support viral infection, and the reduced infection levels with RVFV were specific to 
AMPK activation. 
   Furthermore, we took advantage of a recently developed thienopyridone 
compound A769662 that activates AMPK independently the energy status of cells or 
AMP levels [328,329]. This drug mimics both allosteric activation of AMPK and inhibition 
of dephosphorylation without affecting binding of AMP to the gamma subunit [330]. 
Activation in the presence of this drug requires phosphorylation by an upstream 
activator, but is not specific to a particular upstream pathway [330]. We tested the ability 
of this drug to inhibit viral infection in U2OS cells and MEFs.  RVFV infection was 
significantly reduced in the presence of this compound (Figure 4.3C), indicating that 
AMPK activation restricts RVFV infection independently of the pleiotropic effects of 
reduced cellular energy levels. Furthermore, we tested whether A769662 has AMPK-
independent effects on infection [331], by comparing the activity of the drug against virus 
in wild type and AMPK deficient MEFs. A769662 treatment significantly inhibited RVFV 
infection in wild type MEFs but not in AMPKα1/AMPKα2-/- MEFs (Figure 4.3D). Taken 
together, these studies suggest that energy-mediated AMPK activation has antiviral 
activity against RVFV. 
d. Acetyl CoA Carboxylase Activity Is Inhibited by AMPK Expression and Activation 
 AMPK regulates several downstream pathways that could be important for viral 
infection, in particular protein translation and lipid synthesis. AMPK regulates translation 
through multiple pathways, inhibiting translation initiation by inactivating mTORC1, and 
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inhibiting translation elongation by inactivating eEF2 [204,220,221]. To investigate how 
AMPK is able to restrict RVFV infection, we first examined the role of mTORC1 signaling 
in RVFV infection with or without AMPK expression. Inactivation of mTORC1 by AMPK 
leads to decreased translation initiation as well as increased autophagy, both of which 
could be anti-viral [204]. Since AMPK activation inhibits mTORC1 activity, we 
hypothesized that mTORC1, and thus protein synthesis, would be overactive in AMPK 
deficient cells. We tested the role of mTORC1 signaling in RVFV infection using the 
mTORC1 inhibitor Rapamycin, and found no significant difference in RVFV infection in 
cells treated with Rapamycin compared to vehicle controls in either wild type or 
AMPKα1/AMPKα2-/- MEFs , indicating that the mechanism of antiviral activity does not 
occur through mTORC1 signaling (Supplementary Figure 15).  Furthermore, since 
autophagy has been shown to have antiviral effects in some models [192], we performed 
plaque assays to test whether autophagy restricted RVFV, and found no significant 
difference in plaque number or size in MEFs expressing a Atg5 hairpin compared to 
control MEFs (Supplementary Figure 16).  
Next, we examined phosphorylation of several downstream targets of AMPK. 
eEF2 is an important regulator of translation initiation, while ACC regulates fatty acid 
metabolism [222,231]. Both are inactivated by phosphorylation downstream of AMPK 
[173]. We tested the ability of AMPK-activating drugs to induce phosphorylation of these 
downstream targets in WT or AMPKα1/AMPKα2-/- MEFs.  Cells were treated with AMPK 
activating drugs for 1 hour, lysates were collected and phosphorylation was measured 
by immunoblot using phosphor-specific antibodies. In WT MEFs AMPK phosphorylation 
was increased in response to 2DG, oligomycin, and A769662 treatment (Figure 4.4A). 
We observed a concomitant increase in ACC and eEF2 phosphorylation (Figure4.4A).  
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As expected, neither total nor phospho-AMPK was detected in AMPKα1/AMPKα2-/- 
MEFs under any treatment condition. We observed in an increase in eEF2 
phosphorylation in response to treatment with 2DG and A769662 compared to vehicle 
treatment; although the level of eEF2 phosphorylation in AMPK deficient MEFs was 
reduced compared to wild type cells. In contrast, ACC phosphorylation was undetectable 
in the absence of AMPK (Figure 4.4A). ACC, eEF2, and the control protein tubulin were 
expressed equally in wild type and AMPKα1/AMPKα2-/- MEFs (Figure 4.4A). These 
findings suggest signaling pathways other than AMPK are important in regulating eEF2 
phosphoylation during drug treatment, while ACC phosphorylation is exquisitely 
regulated by AMPK.  
 ACC is an important regulator of fatty acid metabolism, both by inhibiting fatty 
acid biosynthesis and activating fatty acid catabolism through beta-oxidation [231][228]. 
Fatty acid biosynthesis is an important component of RNA virus infection since 
numerous RNA viruses proliferate cellular membrane structures for proper formation of 
the viral replication complex [162]. A member of the Bunyavirus family related to RVFV, 
Bunyamwera Virus, was reported to induce formation of a new Golgi-derived tubular 
structure that harbors the viral replication complex [169,332]. Disrupting formation of this 
structure with certain drugs or viral mutants was reportedly associated with decreased 
levels of virus production [332]. Since AMPK activation inhibits fatty acid synthesis by 
inactivating ACC, we tested whether altered levels of AMPK expression and activation 
cause global changes to cellular lipid levels. To this end, we examined levels of cellular 
lipids by staining wild type and AMPKα1/AMPKα2-/- MEFs with the lipophilic BODIPY 
fluorescent dye, and found increased BODIPY staining in cells lacking AMPK compared 
to wild type (Figure 4.4B). Furthermore, wild type MEFs treated with the AMPK activator 
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A769662 had reduced levels of BODIPY staining compared to untreated MEFs, while 
little difference was seen in AMPKα1/AMPKα2-/- MEFs treated with A769662 compared 
to vehicle treated cells (Figure 4.4B). These findings suggest that the absence of AMPK 
leads to overproduction of cellular lipids, while AMPK activation globally inhibits cellular 
lipid levels.  
 AMPK activation leads to increased fatty acid oxidation along with decreased 
fatty acid synthesis. To determine if increased fatty acid oxidation inhibits RVFV 
infection, we pretreated U2OS cells with the fatty acid oxidation inhibitor etomoxir 1 hour 
prior to infection with RVFV. Treatment with etomoxir had no effect on RVFV infection 
(Figure 4.4C, quantified in 4.4D), indicating that fatty acid oxidation is dispensable for 
infection. Therefore, AMPK activation leads to a net decrease in cellular lipids, most 
likely through reduced levels of fatty acid synthesis. The increased levels of cellular 
lipids in AMPKα1/AMPKα2-/- MEFs may be used during viral infection to allow further 
enhancement of the replication complex, leading to increased infection.  
e. Palmitate Rescues AMPK-Mediated Restriction of RVFV 
If AMPK activation restricts RVFV infection by reducing levels of fatty acid 
synthesis, exogenous addition of fatty acids should restore infection. Therefore, we 
tested whether we could bypass the requirement for AMPK-regulated fatty acid 
synthesis by pretreating cells with palmitate, the first product of fatty acid biosynthesis. 
We treated U2OS cells with palmitate overnight, and then added A769662 1 hour prior to 
infection with RVFV to activate AMPK. After 10 hours of infection, cells were fixed and 
stained for RVFV to measure percent infection. In cells treated with the AMPK activator 
A769662 alone, we found a 5-fold decrease in RVFV infection, consistent with our 
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previous findings (Figure 4.5A, quantified in 4.5B). However, addition of palmitate prior 
to treatment with A769662 was able to restore infection nearly to levels seen in 
untreated cells (Figure 4.5A, quantified in 4.5B). We observed a 5-fold increase in RVFV 
infection in cells treated with A769662 and palmitate compared to those treated with 
A769962 alone (Figure 4.5B). Addition of palmitate alone had little effect on infection in 
cells. (Figure 4.5A-B). Taken together, these data suggest that AMPK restricts RVFV 
infection primarily through inhibiting acetyl CoA carboxylase, and fatty acid biosynthesis.        
f. AMPK Restricts VSV and Sindbis Virus 
The requirement for lipid synthesis during infection is not unique to Bunyaviruses. 
Since many RNA viruses that replicate in the cytoplasm require extensive membrane 
modifications and proliferations to support their replication complex [129,162], we tested 
whether AMPK activation is able to restrict other viruses. To this end we tested the 
ability of the Rhabdovirus Vesicular Stomatitis Virus (VSV) and the Alphavirus Sindbis to 
grow in wild type and AMPKα1/AMPKα2-/- MEFs by immunofluorescense. Both VSV 
(Figure 4.6A-B) and Sindbis (Figure 4.6C-D) had a 2-3 fold higher infection in 
AMPKα1/AMPKα2-/- MEFs compared to wild type MEFs. Moreover, both VSV (Figure 
4.6E-F) and Sindbis (Figure 4.6G-H) also had a 2-3 fold increase in percent infection in 
LKB1-/-; Vec  compared to MEFs expressing LKB1, indicating that both AMPK and its 
canonical upstream activator LKB1 restrict additional viruses besides RVFV. To further 
investigate the role of AMPK signaling in VSV infection, we performed and one-step 
growth curve, and found a 2 fold increase in infectious virus production in 
AMPKα1/AMPKα2-/- MEFs compared to wild type MEFs (Figure 4.6I). Finally, VSV 
infection was inhibited in U2OS cells pretreated with AMPK activating drugs 2DG and 
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oligomycin (Figure 4.6J). Taken together our data suggest that AMPK is broadly anti-
viral across disparate virus families, and may represent a novel cellular target for anti-
viral therapeutics.   
3. Discussion 
Arboviruses represent a group of emerging pathogens of both medical and 
agricultural importance for which there are few therapies. RVFV is a particularly 
important member of this group that causes disease both in humans and livestock, and 
is considered a Category A pathogen due to its potential for geographical spread. Here, 
we identified AMPK as a novel antiviral factor that restricts RVFV infection. This 
restriction required the upstream activator LKB1. AMPK activity regulates viral infection 
by reducing fatty acid biosynthesis, an essential process in RVFV infection. We 
extended these studies and found that additional RNA viruses that are known to require 
lipid biosynthesis were also restricted by this pathway. In addition, treatment with drugs 
that activate AMPK restricted infection, suggesting a novel therapeutic strategy for 
infections with RNA viruses.  
AMPK is a central regulator of cellular energy, and regulates numerous cellular 
mechanisms. Evidence suggests that AMPK may be the only physiologically relevant 
regulator of ACC and fatty acid synthesis [228]. AMPK regulates translation at least in 
part through inhibiting eEF2; however our data suggest that there are additional 
regulators of this pathway since eEF2 phosphorylation was observed in the absence of 
AMPK, while ACC phosphorylation was undetectable in AMPK deficient cells (Figure 
4.4A). Therefore, AMPK is a very potent regulator of ACC and fatty acid synthesis, 
making it likely that this regulation is responsible for the anti-viral effects of AMPK on 
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viruses that require fatty acid synthesis. ACC regulates lipid metabolism through a 
number of different mechanisms mediated by production of malonyl CoA . Malonyl CoA 
is important in converting simple essential fatty acids into more complex polyunsaturated 
fatty acids that can be used to build triglycerides and other cellular lipids. It also inhibits 
fatty acid oxidation by inhibiting transport of fatty acids to mitochondria through CPT1, 
and finally malonyl CoA is a substrate for fatty acid synthesis, which drives de novo 
palmitate production. [231]. Our finding that the CPT1 inhibitor had no effect on infection, 
while addition of palmitate was able to rescue RVFV and overcome the restriction 
mediated by AMPK-activating drugs (Figure 4.5) suggests that the ability of AMPK to 
inhibit fatty acid biosynthesis is the most important determinant of AMPK-mediated 
RVFV restriction. Therefore, tight control of fatty acid biosynthesis by AMPK is an 
essential component of cellular intrinsic antiviral responses.  
Importantly, in addition to RVFV, we also found that the Rhabdovirus VSV and 
the Alphavirus Sindbis are also restricted by AMPK and LKB1 (Figure 4.6), and AMPK 
has been implicated to play a role in infections of Hepatitis C virus (HCV). AMPK-
activating drugs inhibit the replication of RNA replicons concomitant with a decrease in 
cellular lipid levels, while knock down of the upstream activator LKB1 led to increased 
replication [291]. Moreover, addition of AMPK-activating drugs such as Metformin to 
current HCV treatment regimens had promising, albeit modest, effects on reducing viral 
loads [278,279]. Like RVFV, VSV, and Sindbis, HCV replication occurs on modified 
cellular membranes, in this case forming a membranous web derived from intracellular 
vesicles, which requires fatty acid synthesis [164,165]. Furthermore, treatment of AMPK-
activating drugs was able to inhibit infectin of HCMV and HIV, consistent with an anti-
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viral role for AMPK [333,334]. Taken together, our evidence suggests a novel and broad 
antiviral restrictive mechanism controlled by the energy sensor AMPK.  
Cellular anti-viral defense incorporates multi-faceted mechanisms to 
nonspecifically protect the host cell from numerous viral infections. While each family of 
virus has different characteristics and strategies for infection, commonalities exist across 
a broad range of disparate viruses.  Many essential features of virus lifecycles are 
conserved across different families, allowing the host immune system to restrict multiple 
viruses by targeting conserved required mechanisms. One such mechanism broadly 
conserved across RNA viruses is membrane proliferation to support the viral replication 
complex. AMPK is a potent inhibitor of fatty acid synthesis required for these membrane 
proliferations, and plays a role in restricting viruses through this mechanism. Since 
AMPK activators are currently in the clinic to treat metabolic disorders including type II 
diabetes [261], perhaps they may provide useful therapeutics against a broad range of 
viral infections.  
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Figure 4.1: AMPK expression inhibits RVFV infection. A. Plaque assays were 
performed on wild type (WT) and AMPKα2 -/- MEFs. Representative data from triplicate 
experiments is shown. B. Quantification of plaques from A. presented as the normalized 
mean+SD of wild type plaques from three experiments;* indicates p<0.05. C. The 
diameter of 30 representative plaques in each duplicate well from A. was used to 
calculate the average plaque area, which is displayed as the normalized mean+SD in 
triplicate experiments; * indicates p<0.05. D. WT or AMPKα1/AMPKα2 -/- MEFs were 
infected with serial dilutions of RVFV, spinoculated 1 hour at 1200 RPM, incubated for 
16 hours to allow viral growth, and processed for immunofluoresence. (RVFV, green; 
nuclei, blue). E. Quantification of D. presented as percent of infected cells. A 
representative of three experiments is shown. F.Time course of RVFV infection in WT 
and AMPKα1/AMPKα2 -/- MEFs. Cells were infected with RVFV, spinoculated, and fixed 
at indicated hours post infection. (RVFV, green; nuclei, blue) A representive of triplicate 
experiments is shown G. One-step growth curve of RVFV in WT or AMPKα1/AMPKα2 -/- 
MEFs.  RVFV grown in WT or AMPKα1/AMPKα2 -/- MEFs for 4, 8, or 12 hours was 
tittered on BHK cells.  
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Figure 4.2: LKB1 expression inhibits RVFV infection: A. RVFV was plaqued on 
LKB1-/-;LKB1 and LKB1-/-;Vec MEFs. Representative data from triplicate experiments is 
shown. B. Quantification of plaques from A. presented as the normalized mean+SD of 
wild type plaques from three experiments;* indicates p<0.05. C. The diameter of 30 
representative plaques in each duplicate well from A. was used to calculate the average 
plaque area, which is displayed as the normalized mean+SD in triplicate experiments; * 
indicates p<0.05. D. RVFV percent infection in LKB1-/-;LKB1 and LKB1-/-;Vec MEFs. 
MEFs were infected with serial dilutions of RVFV, spinoculated 1 hour at 1200 RPM, 
incubated for 16 hours to allow viral growth, and processed for immunofluoresence. A 
representative of triplicate experiments is shown. E. Time course of RVFV infection in 
LKB1-/-;LKB1 and LKB1-/-;Vec MEFs. Cells were infected with RVFV, spinoculated, and 
fixed at indicated hours post infection. A representive of triplicate experiments is shown. 
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Figure 4.3: AMPK activation restricts RVFV. A-B. U2OS cells were pretreated with 
10uM 2DG, 10uM oligomycin or PBS (untreated) for 1 hour and infected with serial 
dilutions of RVFV (A) for 10 hours after spinoculation or vaccinia (B) for 8 hours and 
processed for immunofluorescense. C. U2OS cells were pretreated with 12 mM 2DG, 
100 uM A769662, or PBS for 1 hour and infected with RVFV (MOI 1) for 10 hours after 
spinoculation. D. WT and AMPKα1/AMPKα2 -/- MEFs were pretreated with 100 uM 
A769662 or PBS for 1 hour and infected with RVFV (MOI 1) for 10 hours after 
spinoculation and processed for immunofluorescence. Data are displayed as the 
normalized percent infection relative to the untreated control at MOI 1.25 +SD in 
triplicate experiments; * indicates p<0.05. 
 
 
 
*
*
87 
 
 
Figure 4.4: Acetyl CoA Carboxylase activity is inhibited by AMPK expression and 
activation. A. Phosphorylation of AMPK and downstream effectors in WT and 
AMPKα1/AMPKα2 -/- MEFs.  Cells were treated with AMPK activators 2DG (12 mM), 
oligomycin (OM, 10 uM), and A769662 (100 uM) for 4 hours. Lysates were collected and 
assayed by immunoblot for phospho-AMPK, phospho-ACC, and phospho-eEF2 Total 
protein was assayed for each to ensure equal levels of expression and loading. Tubulin 
was measured as a loading control. B. Lipid levels in MEFs with or without AMPK 
activation. WT and AMPKα1/AMPKα2 -/- MEFs were treated with 100 uM A769662 for 10 
hours and stained for lipids with BODIPY lipophilic fluorescent dye. (BODIPY, red; 
nuclei, blue). C. WT and AMPKα1/AMPKα2 -/- MEFs were pretreated with the fatty acid 
oxidation inhibitor Etomoxir for 1 hour, infected with RVFV by spinoculation for 10 hours, 
and processed for immunofluorescence. (RVFV, green; nuclei, blue) D. Quantification of 
percent RVFV infection from C. Representative experiments are shown.  
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Figure 4.5: Addition of palmitate restores RVFV infection in the presence of 
A769662. A. U2OS cells were pretreated with 100 uM palmitate overnight in low glucose 
medium supplemented with 5% delipidated fetal calf serum. 100 uM A769662 or PBS 
was added 1 hour prior to infection with RVFV (MOI 1). Cells were spinoculated, 
incubated for 10 hours, and processed for immunofluorescence. (RVFV, green; nuclei, 
blue) B. Quantification of A. Data are displayed as the normalized percent infection 
relative to the untreated control at MOI 1.25 +SD in triplicate experiments; * indicates 
p<0.05 compared to untreated vehicle control. 
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Figure 4.6: VSV and Sindbis are restricted by AMPK. A and C. WT or 
AMPKα1/AMPKα2 -/- MEFs were infected with serial dilutions of VSV (A) or Sindbis (C), 
spinoculated 1 hour at 1200 RPM, incubated for 16 hours to allow viral growth, and 
processed for immunofluoresence. (Virus-GFP, green; nuclei, blue). B and D are 
quantifications of A and C displayed as percent infection. E and G. LKB1-/-;LKB1 and 
LKB1-/-;Vec MEFs were infected with serial dilutions of VSV (E) or Sindbis (G), 
spinoculated 1 hour at 1200 RPM, incubated for 16 hours to allow viral growth, and 
processed for immunofluoresence. (Virus-GFP, green; nuclei, blue). F and H are 
quantifications of E and G.Representitives of triplicate experiments are shown. I. One-
step growth curve of VSV in WT or AMPKα1/AMPKα2 -/- MEFs.  VSV grown in WT or 
AMPKα1/AMPKα2 -/- MEFs for 4, 8, or 12 hours was tittered on BHK cells. H. U2OS cells 
were pretreated with 10uM 2DG, 10uM oligomycin or PBS (untreated) for 1 hour and 
infected with serial dilutions of VSV for 10 hours after spinoculation and processed for 
immunofluorescense. Data are displayed as the normalized percent infection relative to 
the untreated control at MOI 10 +/-SD in triplicate experiments; * indicates p<0.05 
compared to untreated vehicle control. 
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V. CONCLUDING REMARKS 
Host interactions play crucial roles in determining the outcome of viral infection. 
These interactions can be required for the virus to complete certain stages of its 
lifecycle, or can restrict viral infection as part of an immune response program, 
depending on the specific stratagies a given virus uses for infection. I took an un-biased 
screening approach to identify host factors that impact vaccinia infection, and ultimately 
discovered a previously unrecognized role for AMPK in infections of multiple disparate 
viruses. AMPK is a central regulator of many cellular processes including protein, 
carbohydrate, and lipid metabolism as well as cytoskeletal regulation, polarity, growth, 
and proliferation, many of which are important for viral infection. While vaccinia requires 
AMPK to modulate the actin cytoskeleton promoting efficient entry (Chapter III), RVFV is 
restricted by AMPK due to its negative regulation of fatty acid biosynthesis (Chapter IV). 
Such complex interactions are not unprecedented. For example, autophagy is required 
for some viruses during their lifecycle, but has also been shown to have antiviral 
functions, specifically against VSV and Sindbis Virus [292,335,336,337,338]. Another 
example is Barrier to Autointegration Factor (BAF), which is required to prevent 
autointegration of the retroviral preintegration complex, but also plays an antiviral role in 
poxvirus infection by preventing DNA replication [37,339]. Therefore, the role of host 
factors during infection is highly dependent on the specific lifecycle requirements of each 
virus, and the discovery of these functions can increase our understanding of viral as 
well as cell biology.  
 
 
91 
 
1. AMPK Promotes Vaccinia Entry 
 AMPK is involved in multiple cellular processes that require modulation of the 
actin and microtubule cytoskeletal networks, including vaccinia virus induced 
macropinocytosis. While AMPK very quickly becomes phosphorylated upon vaccinia 
infection, the cellular signaling pathway leading to this activation remains unclear. Since 
AMPK is expressed cytoplasmically, and is required prior to internalization of vaccinia 
virus, it is unlikely that vaccinia directly phosphorylates AMPK. More likely, vaccinia 
binds to some surface receptor, which initiates a signaling cascade ultimately leading to 
AMPK phosphorylation. Epidermal Growth Factor Receptor (EGFR) has recently been 
identified as a receptor important for vaccinia entry through macropinocytosis [84]. 
EGFR activation is known to stimulate Rac1-mediated actin modifications such as 
filament stabilization and Arp2/3-dependent actin polymerization that contribute to 
macropinocytosis [87]. Since Rac1 mobilization during PMA treatment is defective in 
AMPK deficient MEFs (Figure 3.7B) and Rac1 activation downstream of AMPK has been 
reported [314,315], it would be interesting to determine if AMPK is phosphorylated in 
response to EGFR stimulation, and if EGFR-induced actin dynamics are defective in 
AMPK deficient cells. This would provide a link between engagement of a receptor by 
vaccinia, downstream activation of AMPK, and induction of macropinocytosis.  
 The immediate upstream activator of AMPK under these conditions remains 
unclear. I have shown that neither LKB1 nor CaMKKβ are required for vaccinia infection 
(Figure 3.4), suggesting that AMPK phosphorylation occurs through some other route. 
This is in contrast with previous polarity studies that have demonstrated that LKB1 is an 
important mediator of cell polarity at least in part through AMPK signaling 
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[175,236,237,242,243]. Recent studies with the AMPK activator A769662 have indicated 
that expression of LKB1 or CaMKKβ is required for A769662-induced phosphorylation of 
AMPK, but the specific upstream activator was unimportant and may vary in different cell 
types depending on which is highly expressed [330]. LKB1 activity is believed to be 
constitutive, with dephosphorylation by protein phosphatase 2Calpha being most 
strongly responsible for its regulation of AMPK [183,340,341]. It is possible that LKB1 
and CaMKKβ play redundant roles in vaccinia-mediated AMPK phosphorylation so that 
interfering with one of the upstream activators still allowed phosphorylation by the other. 
Dually inhibiting both LKB1 and CaMKKβ during vaccinia infection could clear up this 
issue. Alternatively it is possible that AMPK is phosphorylated by TAK1 or a novel 
upstream activator in response to vaccinia infection. 
 Rho-family GTPases regulate actin cytoskeletal structures in response to 
external stimuli. Specifically, Rac1 is involved in membrane ruffling, wound healing and 
macropinocytosis discussed in Chapter III. I found a defect in Rac1 mobilization to the 
plasma membrane in response to PMA treatment in AMPK deficient MEFs (Figure 3.7B), 
indicating that AMPK is important in signaling this event. Studies have shown that Rac1 
is activated in response to vaccinia infection, and this activation is required for vaccinia 
entry through macropinocytosis [83]. However the virus strain used in these studies was 
WR, as I used in Chapter III. A different strain of vaccinia IHDJ employs a different type 
of macropinocytosis in which stable filopodia are formed during infection, rather than the 
transient actin blebs induced by WR [84]. Moreover, while both virus strains induced 
activation of both Rac1 and Cdc42, WR entry was dependent on Rac1, while IHDJ entry 
was dependent on Cdc42 [84]. Since the form of macropinocytosis employed by IHDJ is 
clearly different from WR and likely involves different upstream signaling events, it would 
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be interesting to determine if IHDJ entry is also dependent on AMPK, as I would expect 
if AMPK is specifically involved in Rac1-mediated actin modulation, rather than Cdc42.  I 
found that like vaccinia WR, cowpox virus requires AMPK for efficient infection (Figure 
3.3D). The mechanism of cowpox entry has not been well characterized, so it is unclear 
if this virus enters by macropinocytosis, and if its entry is dependent on Rac1 or Cdc42. 
These studies may help to further elucidate the role of AMPK in macropinocytosis and 
poxvirus infection.  
 During infection several mature forms of vaccinia are produced. Mature virus 
(MV) consists of the virus core surrounded by one lipid bilayer envelope that contains 
associated membrane proteins including the vaccinia entry-fusion complex [77]. MV 
remains in the cytoplasm of an infected cell, and is released only upon cell lysis. This is 
the more stable form of the virus believed to be responsible for host to host 
transmission. Extracellular virus (EV) consists of an MV particle wrapped in an additional 
Golgi-derived membrane studded with a different set of viral proteins. EV is released 
from the cell by fusion at the plasma membrane, and can either disseminate or 
reassociate with the cell (CEV) through interactions with the actin cytosketon to propel 
itself on actin tails [11]. Studies have suggested that MV and EV may use different 
strategies for entry since requirements and kinetics of entry were different [78]. CEV 
entry is not well understood [77]. It would be interesting to investigate the role of AMPK 
in entry of the EV form of the virus in order to compare the importance of this host factor 
in both mature forms of the virus.  
 Since EV particles interact with the actin cytoskeleton upon egress to form CEV, 
it is possible that AMPK could play a role in this process as well. This idea is further 
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supported by Figure 3.3A-C in which I show both a decrease in plaque number and 
plaque size in cells lacking AMPK. The decrease in plaque number is likely due to 
decreased infectivity resulting from inefficient entry in the absence of AMPK. The 
decrease in plaque size could be due to decreased virus production or inefficient spread. 
Although fewer cells become infected in cells lacking AMPK, those that do become 
infected are able to complete all replicative stages of vaccinia infection (Supplementary 
Figure 11A), making decreased virus production less likely. Furthermore, in a one step 
growth curve, I found approximately a 2-fold reduction in vaccinia produced in AMPK 
deficient cells, consistent with our observed 2-fold reduction in vaccinia entry 
(Supplementary Figure 11B). Since there was no further decrease in vaccinia 
production, I believe virus production to be comparable in WT and AMPK deficient cells. 
Therefore, it is likely that the small plaque size observed in these cells is due to 
decreased spread. This decrease in spread could result from an entry block in 
subsequent rounds of infection, or it could result from an inability of CEV to form actin 
tails. Since actin modulation is required for tail formation and vaccinia spread, AMPK 
could play a role in this process as well as in entry, and it would be interesting to 
investigate this possibility.  
2. AMPK Restricts RNA Viruses 
While vaccinia virus requires AMPK for efficient infection, several RNA viruses 
examined in this study were restricted by AMPK expression and activation. RVFV was 
very dramatically inhibited, while VSV and Sindbis virus were moderately restricted 
(Figure 4.1 and 4.6). I found that this restriction was dependent on the upstream 
activator LKB1 (Figure 4.2 and 4.6), and signaling mediated through low energy 
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conditions was able to control infection (Figure 4.3). This is in contrast to our studies with 
Vaccinia virus, in which LKB1 deficiency or treatment with energy-lowering AMPK-
activating compounds had no effect on infection (Figure 3.4). Furthermore, while AMPK 
is required for vaccinia entry through macropinocytosis, VSV and Sindbis enter cells 
through clathrin-mediated endocytosis and RVFV enters through a Rab5 and Rab7 pH-
dependent endocytic route that has not been well characterized [342]. I tested the ability 
of cells lacking AMPK take up transferrin through clathrin-mediated endocytosis, and 
found that this endocytic route is intact in AMPK deficient cells and has similar efficiency 
to WT MEFs (Supplementary Figure 12). Therefore, it is clear that the role of AMPK in 
RNA virus infection occurs through a very different mechanism than I observed for 
Vaccinia virus. The upstream activation pattern is distinct, as well as the downstream 
mechanism of viral action.  
 I have shown that vaccinia virus induces AMPK phosphorylation (Figure 3.4C). It 
is unclear if infection with these RNA viruses induces a similar increase in 
phosphorylation. Studies with the RNA virus HCV have indicated that expression of HCV 
proteins from a stably-expressed replicon inhibits AMPK activity through an Akt-
mediated pathway in hepatocytes [291]. Since HCV infection is also inhibited by AMPK 
activation, it is likely that the virus encodes some mechanism to counteract the negative 
effects of AMPK by promoting dephosphorylation, but it is unclear which viral proteins 
are responsible for this effect. I have some data to suggest that VSV is also able to 
inhibit phosphorylation of AMPK or its downstream target ACC (data not shown), but this 
idea must be further explored.  
96 
 
It is unclear if AMPK activity provides a constitutive anti-viral presence since 
there is some level of basal AMPK phosphorylation, or if AMPK is specifically induced 
upon viral infection. Distinguishing between these possibilities could be difficult if these 
viruses do indeed encode mechanisms to inhibit AMPK phosphorylation. Testing 
individual non-infectious components, such as UV-inactivated virus particles, virus like 
particles, the ribonucleoprotein, or the naked RNA genome may help to resolve this 
issue. Infection is likely to introduce new stresses and energy demands on the cell, 
which may cause a local, if not global increase in AMPK phosphorylation, leading to viral 
restriction. This could be determined by measuring cellular energy levels during 
infection.  Alternatively, it is possible that AMPK becomes activated in response to some 
viral sensing program. TAK1 has been implicated as an upstream activator of AMPK 
[190], and also participates in activation of innate immune signaling downstream of toll-
like receptors and the cytoplasmic NOD sensors [193,194,195,196]. It is therefore 
possible that recognition by some of these sensors could lead to AMPK activation. While 
treatment with LPS has shown a decrease in AMPK phosphorylation in certain cell 
types, agonists to other sensors have not been tested. It would be interesting to treat 
cells with a variety of sensor agonists, and examine the effect of treatment on AMPK 
phosphorylation. This may help to determine if innate immune signaling pathways 
contribute to AMPK activation and viral restriction.    
Taken together with published reports, evidence suggests that members of at 
least four different RNA virus families may be restricted by AMPK. I have shown that 
restriction of RVFV is mediated through AMPK’s inhibition of fatty acid synthesis, and 
correlative studies indicate the same may be true for HCV [291]. It will be important to 
further investigate the role of AMPK in VSV and Sindbis infection to determine if 
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restriction occurs by the same mechanism for these viruses. Furthermore, it will be 
important to test additional disparate viruses to examine the full range of AMPK 
mediated restriction.  RVFV, VSV, SINV, and HCV are all enveloped single-stranded 
RNA viruses that replicate in the cytoplasm. These viruses require manipulation of 
cellular lipids at two distinct stages of their lifecycle. They rearrange and proliferate 
internal cellular membranes into vesicle-like structures to support their replication 
complex, and also require cellular lipids during assembly when they are encapsulated in 
a cellularly-derived lipid envelope. It is unclear whether AMPK activation interferes with 
the replication complex or encapsulation steps or both. While non-enveloped viruses 
such as Polio Virus do not require this membrane encapsulation step, many still require 
membrane rearrangements to support their replication complex. Determining if non-
enveloped viruses are also restricted by AMPK could help to provide an answer. 
Additional studies with viruses that replicate in the nucleus such as Influenza virus could 
further elucidate the spectrum of viruses that are restricted by AMPK.  
Several classes of AMPK-activating pharmaceuticals are already in use for 
treatment of type II diabetes. These drugs may also have uses as antiviral therapeutics, 
but first it will be important to establish if they have antiviral effects in vivo. Metformin 
and TZDs are believed to activate AMPK indirectly and have other targets during 
treatment. Since they are associated with negative side effects, development of more 
specific AMPK activators to treat viral infection may be beneficial. Therefore it is 
important to investigate if AMPK activation itself is antiviral in vivo. To perform this study, 
mice should be treated with the specific AMPK activator A769662 along with clinically 
approved anti-diabetic drugs that activate AMPK and infected with a panel of viruses 
known to be restricted by AMPK. Finally, since groups of diabetic patients have been 
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closely monitored, it may be possible to perform epidemiological studies to determine if 
patients receiving Metformin or TZD treatment show decreased incidence of viral 
infection. Similar studies have been already been used to link Metformin treatment with 
decreased risk of cancer, and could also be beneficial in investigating infectious disease. 
These studies could be very helpful in developing broadly anti-viral therapeutics that 
target AMPK. 
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VI. APPENDIX: SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: Vaccinia infection in Drosophila cells. A. Drosophila DL1 
cells were infected with vaccinia virus expressing B-gal driven by an early/late promoter 
(p7.5) for indicated time, and stained for X-gal production. A representative of 2 
experiments is shown. B. Titration of vaccinia infection in Drosophila cells seeded in 384 
well plates. Cells were fixed and processed 48 hpi and stained for early B-gal expression 
(green) and nuclei (blue). C. Quantification of B. Percent  infection is the average of 6 
wells, with 3 images per well in duplicate experiments. Bars represent average percent 
infection for each experiment.  
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Supplementary Figure 2: Inhibitors of macropinocytosis inhibit vaccinia infection 
in mammalian and Drosophila cells. A. Human U2OS cells were pretreated with: 
Latrunculin A (Lat A, 5μM), Wortmannin (Wort, 5μM), Rottlerin (10μM), or EIPA (12.5μM) 
for 1 hour, challenged with vaccinia (MOI=10) for 8 hours, and quantified for percent 
infection. B. Drosophila DL1 cells were treated with: Latrunculin A (Lat A, 5μM), 
Wortmannin (Wort, 5μM), and Rottlerin (5μM), or EIPA (50μM) for 1 hour and challenged 
with vaccinia (MOI=20) for 24 hours. Cells were fixed and processed for 
immunofluorescence using E3L expression as a marker for infection, and Hoescht 
33342 to visualize nuclei. Mean percent infection + SD in triplicate experiments is 
shown; * indicates p<0.05 compared to control in three independent experiments. 
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Supplementary Figure 3: Validation of eight candidates that promote vaccinia 
infection identified in RNAi screen of Drosophila kinases and phosphatases.  
Independent dsRNA targeting different sequences of each candidate gene were tested, 
and percent infection was determined by immunofluorescence measuring B-gal 
expressing cells. Luciferase was used as a nontargeting negative control. B-gal and 
Rab5 were added as positive controls for decreased infection. A representative of 
duplicate experiments is shown. Error bars represent standard deviation of 12 different 
wells with 3 images taken per well. * indicate p-value of <0.001 in both experiments.    
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Supplementary Figure 4: dsRNA against AMPKα or LKB1 leads to depletion of the 
cognate mRNA in Drosophila cells. RNAi was performed against luciferase (luc) or 
AMPKα (A) or LKB1 (B) in Drosophila cells. RNA was collected from lysates and RT-
PCR was performed to measure mRNA levels. A 1:10 dilution of control cDNA (luc) was 
included to demonstrate that the depletion was greater than 10-fold. Clathrin heavy 
chain (chc) was used as a loading control. 
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Supplementary Figure 5: AMPKα1/AMPKα2 -/- MEFs do not express AMPKα. Wild 
type or AMPKα1/AMPKα2 -/- MEF protein lysates were collected and probed by 
immunoblot for total-AMPKα and tubulin.  
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Supplementary Figure 6: AMPK promotes efficient cowpox virus infection. Plaque 
assays were performed on wild type or AMPKα1/AMPKα2 -/- MEFs and quantified in 
duplicate experiments. Error bars show the individual values; * p<0.05 in each replicate. 
 
 
 
 
 
 
 
 
105 
 
 
Supplementary Figure 7: AMPK is not required for Vesicular Stomatitis Virus 
infection. Plaque assays were performed on wild type or AMPKα1/AMPKα2 -/- MEFs. 
There was no decrease in plaque number observed in the mutant cells. A representative 
experiment of three is shown.  
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Supplementary Figure 8: AMPK promotes early vaccinia infection in mammalian 
cells.  A. Lack of AMPKα leads to decreased vaccinia infectivity in MEFs. Wild type or 
AMPKα1/AMPKα2 -/- MEFs were infected with the indicated MOI for 8 hours and 
processed for immunofluorescence.  Data is displayed as average percentage of 
infected cells for a representative experiment. B. Loss of AMPKα leads to a decrease in 
viral mRNA production in AMPKα1/AMPKα2 -/- MEFs. Northern blot of viral mRNA levels 
in WT or AMPKα1/AMPKα2 -/- MEFs at indicated times post infection (MOI=10). Blots 
were probed for virally encoded E3L or a ribosomal RNA loading control. C. Wild type or 
AMPKα1/AMPKα2 -/- cells were infected (MOI=10) for the indicated times and probed for 
E3L by immunoblot 
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Supplementary Figure 9: siRNA targeting AMPK inhibits vaccinia infection in 
mammalian cells. A. U2OS cells were treated with non-targeting siRNA (siCON) or 
siRNA targeting AMPKα1 or AMPKα2 and infected with vaccinia virus (MOI 10), and 
stained for E3L expression after 8 hours. B. Quantification of percent infection from A. 
The average of duplicate experiments; error bars represent mean of the percent 
infection for each experiment. C. Western blot probing total AMPKα after siRNA 
treatment.  
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Supplementary Figure 10: LKB1 cDNA rescues the LKB1 null cells. LKB1 -/- MEFs 
were complemented with a vector control (Vec) or FLAG-LKB1 (LKB1) cDNA and were 
mock treated, or treated with 2-deoxyglucose (2DG) which leads to LKB1-dependent 
AMPK phosphorylation for 30 min. Protein lysates were collected and probed by 
immunoblot for FLAG, phospho- or total-AMPKα expression.  
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Supplementary Figure 11: Vaccinia produced in AMPK deficient cells is infectious.  
A. AMPK is not required for late vaccina protein expression. WT and AMPKα1/AMPKα2 -
/- MEFs infected with vaccinia for 8 hours were stained for early (E3L, green) and late 
(L1R, red) vaccinia protein expression.  B. Infectious virus is produced in AMPK deficient 
cells. Vaccinia grown for 12 hours in WT and AMPKα1/AMPKα2 -/- MEFs was titered in 
BSC-1 cells. Rifampicin (Rif) was added as a control for detecting incoming virus. The 
relative pfu/ml in BSC-1 cells was graphed as the mean + standard deviation of triplicate 
experiments. The decrease in virus produced was similar to decrease in virus entry.   
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Supplementary Figure 12: AMPK deficient cells undergo efficient receptor-
mediated endocytosis.  Transferrin uptake assays were performed in the presence or 
absence of virus. Wild type and AMPKα1/AMPKα2 -/- MEFs were either infected or 
mock-infected and treated with 594-transferrin (red), processed for microscopy, and 
stained to visualize actin (phalloidin (green)) and nuclei (Hoescht 33342 (blue)). 
Representative images from triplicate experiments are shown. 
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Supplementary Figure 13: AMPK deficient cells are defective in lamellipodia 
formation during wound healing. A scratch was made in a confluent monolayer of wild 
type or AMPKα1/AMPKα2 -/- MEFs, and monitored over time. Images were taken using a 
20X and 63X objective immediately after wounding (T=0), and again after 3 and 6 hours 
to determine the morphology of the cells at the wound front. Polarized cells with 
lamellipodia are visible at the wound front of wild type MEFs (arrows). Representative 
images from triplicate experiments are shown.  
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Supplementary Figure 14: Cellular motility is LKB1-independent.  Scratches were 
introduced into a confluent monolayer of LKB1 -/- , Vec or LKB1 -/-; LKB1 cDNA MEFs, 
and monitored over time for closure. Representative images from triplicate experiments 
are shown immediately after wounding (T=0) and after 12 or 24 hours. The reduction in 
wound width is quantified over time. Data are normalized to initial would width at T=0, 
and presented as means of three independent experiments with four wounds per set.   
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Supplementary Figure 15: mTORC1 is not required for AMPK-mediated restriction 
of RVFV. WT and AMPKα1/AMPKα2 -/- MEFs were pretreated with 10 nM Rapamycin or 
PBS for 1 hour and infected with RVFV (MOI 1) for 10 hours after spinoculation and 
processed for immunofluorescence. A representative of duplicate experiments is shown. 
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Supplementary Figure 16: RVFV is not restricted by autophagy. Plaque assays 
were performed with RVFV on MEFs stably expressing a hairpin RNA targeting Atg5 or 
a control hairpin. 
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